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ABSTRACT 
 
In this thesis, the primary motivation was to develop a strategy to help improve the treatment of 
hypertension in patients with obstructive sleep apnoea (OSA), and to discover new biomarkers of risk 
that can be used for future prognostication and for therapeutic interventions. A central theme 
throughout is the emphasis on analysing and targeting the 24 hour blood pressure profile of patients 
with OSA, given our newer understanding that nocturnal blood pressure is the strongest predictor of 
cardiovascular mortality.   
Chapter 1 in this thesis is a comprehensive literature review covering blood pressure physiology, the 
pathophysiology of hypertension and arterial stiffness both in non-OSA and OSA populations and 
treatment strategies including chronotherapy. Hypertension is a leading risk factor for cardiovascular 
morbidity and mortality and the treatment of hypertension significantly reduces this risk. OSA is 
strongly associated with hypertension, and has been recognised as a leading cause of secondary 
hypertension. Current literature suggests that patients with OSA not only have a much higher 
prevalence of hypertension, but that it is more difficult to treat in this population, likely due to the 
differing underlying pathophysiology. Furthermore, patients with OSA frequently suffer nocturnal 
hypertension and a non-dipping blood pressure profile which are strong prognostic markers of poorer 
cardiovascular outcomes.  Despite this, specific guidelines on how to manage hypertension in OSA do 
not exist apart from the recommendation of the implementation of continuous positive airway 
pressure (CPAP). Numerous randomised controlled trials demonstrate that CPAP reduces blood 
pressure by only 1-2mmHg and is ineffective as stand-alone therapy. Newer treatment strategies to 
help improve blood pressure control in this vulnerable group are needed, as is a better understanding 
of the underlying arterial haemodynamics.  
In the first study presented in chapter 2 in this thesis (published in the journal Thorax with editorial), 
we explore the use of chronotherapy, or the altered timing of once-daily medication administration, 
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in an effort to improve the blood pressure control of patients with OSA. This simple strategy has 
previously been shown to be remarkably effective in reducing nocturnal BP in patients with essential 
hypertension. We hypothesised that nocturnal dosing (compared to morning dosing) of a once daily 
anti-hypertensive would achieve greater reductions in nocturnal blood pressure in OSA patients whilst 
achieving equivalent reductions in daytime blood pressure. We explored this using a robust 
randomised double blinded placebo-controlled cross-over trial in 79 patients with moderate to severe 
OSA with grade 1 or 2 hypertension. We administered either morning or evening Perindopril (an 
Angiotensin Converting Enzyme Inhibitor) at a maximum dose of 10mg with matching placebo at the 
opposite time-point, and measured ambulatory blood pressure profiles over 24 hours. In contrast to 
the previous studies in non-OSA populations, we found that nocturnal administration of the anti-
hypertensive was not superior in lowering nocturnal blood pressure as we had expected. This 
highlights the complexities of the OSA hypertensive population and the potential differences in 
underlying pathophysiology. Importantly, our study represented the first placebo controlled 
chronotherapy in hypertension study in any population to date which further strengthens the 
robustness of the findings. 
In the second study presented in chapter 3 of this thesis (submitted for publication – undergone first 
revision stage), we explored 24 hour arterial haemodynamics in patients with OSA as a novel 
biomarker for future risk stratification and therapeutic interventions. We used state-of-the-art 
technology to capture 24 hour central blood pressure in patients with OSA with the use of a non-
invasive ambulatory device. Recent studies have shown that central blood pressure may serve as a 
better prognostic indicator as compared to peripheral blood pressure, and that anti-hypertensives 
exert differential effects on central versus peripheral blood pressure. Our study provides the first 
description of the 24 hour central blood pressure profile in patients with OSA. We confirmed that 
central and peripheral blood pressures behave differently over a 24 hour period, in particular, with 
variable reductions in pulse pressure overnight.  Targeting central blood pressure in patients with OSA 
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instead of peripheral BP with therapeutic interventions (CPAP, or anti-hypertensives) may yield 
greater cardiovascular benefits and has important clinical implications.  
In the final chapter we summarise the key findings of our studies and briefly discuss future directions. 
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1 CHAPTER ONE 
Literature review   
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1.1 CHRONOTHERAPY 
 
Circadian rhythms were first discovered in 1729, when the astronomer Jean-Jacques d’Ortous de 
Mairan found that the daily leaf movements in a plant continued in darkness, suggesting that the 
plant’s internal physiology, or biological clock, controlled its daily movements. In 1959, Franz Halberg 
created the term “circadian,” Latin for circa=about and dies=day, to describe the endogenous 
biological rhythms that occur over a 24 hour period.1 We have come to discover that specific genes 
are responsible for circadian rhythm generation in all organisms, from eukaryotes to humans. These 
genes are controlled by an internal circadian clock and expressed rhythmically at various times during 
the day.1 
 
In humans, the central pacemaker that controls these circadian rhythms is located in the 
suprachiasmatic nucleus (SCN) of the hypothalamus, sending out signals to peripheral clocks located 
in all tissue and organ cells.  The SCN regulates almost all physiological processes and behaviours, such 
as the sleep-wake cycle, and hormone levels.2 
 
Drug pharmacokinetics is also under chronobiological control, affecting the absorption, distribution, 
metabolism and elimination of drugs. Hence the time of day that a drug is delivered may alter its 
pharmacokinetic effect. This is because factors such as gastric pH, gut motility, liver and renal 
perfusion, liver metabolism and renal output are all under circadian rhythmic physiological control. 3 
Similarly, the molecular target of a drug may be less or more available during the day due to factors 
such as membrane permeability or receptor density and sensitivity, affecting the pharmacodynamics 
of the drug. 3 
 
Hence, circadian biology has been gaining traction over the last two decades in terms of its therapeutic 
implications. Understanding that human physiology is not static has led us to appreciate that drug 
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delivery should take into consideration the chrono-pharmacokinetic and chrono-pharmacodynamic 
properties of the drug to elicit a maximal response.  
 
Chronotherapy is the purposeful timing of medications in line with circadian rhythms to enhance the 
effect of the medication and to reduce unwanted side effects.4 Zhang et al recently discovered that 
more than 50% of all drugs target circadian genes, including 119 of the WHO’s list of essential 
medicines. 5 
 
By using these principles, studies have shown for example that evening administration of slow release 
indomethacin as opposed to morning administration in patients with osteoarthritis reduced undesired 
side effects from 33% to 7%.3 Similarly, altered timing of chemotherapy agents has improved the 
tolerability and anti-tumour activity of various anti-cancer drugs.3  
 
Chronotherapy has established itself as the new frontier for drug therapy. One important area of 
interest for its application has been in the control of blood pressure. As will be described in the 
following section, blood pressure displays 24-hour variation, dipping at night and rising in the morning. 
Elevated nocturnal blood pressure and lack of nocturnal dipping have been associated with adverse 
cardiovascular outcomes, and the morning surge in blood pressure has been associated with a high 
risk period for fatal cardiovascular events (see below). Hence, targeting blood pressure control during 
the nocturnal and early morning period has gained much attention of late. 
 
1.2 BLOOD PRESSURE 
 
1.2.1 Blood pressure physiology 
 
Since the late 1800s it has been known that blood pressure is lower at night6. In 1978, Millar-Craig et 
al were the first to perform 48 hour ambulatory intra-arterial blood pressure monitoring in twenty 
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untreated hypertensive patients and 5 normotensive patients using left brachial artery cannulation!6 
This fascinating study found that in the hypertensive patients, blood pressure was highest in the 
morning and fell throughout the day. The nadir was reached at 3am after which the blood pressure 
rose quickly, and this rise accelerated after awakening at 7am reaching a peak at 10am. A very similar 
pattern was noted in the smaller normotensive group. The authors alluded to the practice of 
chronotherapy at the time, when they pointed out that antihypertensive treatment should target this 
early morning rise in blood pressure. This is because the scientific community had already discovered 
that the early morning period is associated with a high incidence of strokes and myocardial 
infarctions.7   
In normotensive and uncomplicated hypertensive patients, blood pressure lowers during sleep, rises 
somewhat abruptly during awakening and peaks during the first few hours of wakefulness. 8 Normal 
nocturnal dipping is when the mean blood pressure lowers during sleep by roughly 10-20% as 
compared with wake mean blood pressure. A healthy young adult may increase their systolic blood 
pressure by 20-25mmHg on waking. A night time lowering of less than 10% classifies an individual as 
a “non-dipper”, and an increase in night time blood pressure classifies an individual as a “reverse 
dipper.”9 Certain disease states that affect the endocrine, autonomic nervous system, or 
cardiovascular system such as obstructive sleep apnoea, chronic renal failure and severe 
hypertension, are associated with either a non-dipping status or reverse dipping. 9 
The exact mechanism for the normal diurnal variation in blood pressure is still not yet completely 
understood and mechanistic studies in humans are sparse. Many people have labelled BP as being 
“circadian” simply because it has a diurnal pattern. However, displaying a diurnal pattern does not 
mean that it is driven by the circadian clock. BP is very closely linked to the 24 hour sleep-wake cycle, 
but is also influenced by a myriad of physiological factors (posture, exercise), as well as behavioural 
and environmental factors (stress, caffeine, salt).10 11 Physical activity or exercise increases blood 
pressure significantly, whereas immobilization or lying supine, decreases blood pressure.10 BP drops 
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during sleep, and a study of shift workers demonstrated that even if sleep is reversed to occur during 
the daytime, blood pressure dipping occurs during the day sleep and rises during wakefulness at night 
time, leading the authors to conclude that the sleep-wake cycle and not the circadian clock was 
responsible for the diurnal rhythm. 8 Similarly, another small study found that in forced wakefulness 
throughout a 24 hour period and in an environmentally and behaviourally controlled environment, 
there was no diurnal variation in BP, again suggesting a lack of circadian control.12 However, the most 
sophisticated human study which included a 28 hour and a 20 hour “forced desynchrony” protocol 
(involving progressive shifts of the sleep-wake times over several days), as well as concurrent 
monitoring of the circadian phase using core body temperature, found that the peak BP consistently 
occurred at the biological time of 9pm.13  This study, in contrast, supports the theory of an underlying 
endogenous circadian control of BP. However, what was not specifically commented on in this study, 
was the finding of the unusually small variations in peak and trough BP (averaging between 3 to 6 
mmHg in systolic BP), as compared to the usual much larger variation seen in humans on a normal 
sleep-wake routine.   Undoubtedly, the diurnal variation in BP is both a function of the endogenous 
circadian clock as well as sleep-wake influences. Human genome-wide association studies have not 
been able to associate blood pressure control with clock genes. 14    
From a physiological perspective, it appears that it is mainly the activity of the autonomic nervous 
system and various other neuro-hormonal processes such as the renin-angiotensin system that result 
in changes in blood pressure.  During wakefulness, the sympathetic nervous system is more active, 
whilst during sleep the parasympathetic nervous system (vagal tone) is more prominent.9. In support 
of this, plasma levels of norepinephrine and epinephrine (hormones associated with the sympathetic 
nervous system) are highest in the morning and lowest during sleep. The same pattern has been found 
for urinary catecholamines, demonstrating a circadian pattern.9  Similarly, renin levels have been 
found to be higher in sleep and lower in wakefulness.15 
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Notably, the different stages of sleep are associated with changes in BP. Deep sleep (Stage 3 and 4 
NREM sleep, otherwise known as N3 sleep) is associated with lower BP and REM sleep is associated 
with higher BP. This corresponds to the activity of the ANS. Sympathetic activity is low in deep NREM 
sleep, whereas in REM sleep it can be the same or higher than levels in wake.9 In fact BP can rise up 
to 30-40mmHg higher than baseline during REM sleep.9  
In clinical conditions where the normal circadian variation in autonomic nervous system activity has 
been perturbed such as in diabetes with autonomic neuropathy, the normal circadian BP dip can be 
absent or attenuated.9 Similarly, in obstructive sleep apnoea, where there is nocturnal over-activation 
of the sympathetic nervous system due to repetitive intermittent hypoxic insults, non-dipping appears 
to be quite common. 16-18 
1.2.2 Hypertension – definition, prevalence and mortality risk 
 
Hypertension is defined as a clinic systolic blood pressure of ≥ 140mmHg and/or diastolic blood 
pressure ≥ 90mmHg, as measured on more than one occasion.19 However, elevated blood pressure is 
linearly correlated with increased cardiovascular risk and hence cut-off values are arbitrary and differ 
with various international guidelines.19 For instance, the most recent 2017 American College of 
Cardiology-American Heart Association guidelines have lowered their diagnostic threshold for 
hypertension to SBP ≥ 130mmHg and/or DBP ≥ 80mmHg.20 This change was based on the results of 
the Systolic Blood Pressure Intervention Trial (SPRINT) which randomly assigned roughly 9000 patients 
>50yo at high cardiovascular risk to a target blood pressure of either <140mmHg or <120mmHg. The 
group assigned to the lower BP threshold had significantly fewer cardiovascular events and lower all-
cause mortality,21 with the number needed to treat of 61 to reduce one cardiovascular event over a 3 
year period.21 The more intensive lower threshold was not without adverse effects, with patients 
randomised to that arm suffering greater events including syncopal episodes, acute kidney injury and 
hypotension (4.7% vs 2.4%).21 Given the population studied was selective and not generalizable, and 
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lacking in long term adverse effect data, the Australian guidelines continue to recommend a blood 
pressure target of <140/90 for the majority of individuals.19 
The severity of hypertension is categorised into Grade 1 (mild) – SBP 140-159 and/or DBP 90-99, Grade 
2 (moderate) – SBP 160-179mmHg and/or DBP 100-119mmHg, Grade 3 (severe) -  SBP≥  180 and or 
DBP ≥ 110 or isolated systolic hypertension – SBP >140mmHg and DBP <90mmHg. Resistant 
hypertension is defined as SBP>140, despite being on at least 3 anti-hypertensive medication classes 
including a diuretic, at optimal tolerated doses. 19 
The prevalence of hypertension in Australia in 2012-2013 was 34% (6 million individuals), as defined 
by BP ≥ 140/90 or if taking anti-hypertensive medications. 19 68% of this population had untreated or 
uncontrolled hypertension.19 
Blood pressure is an independent predictor of cardiovascular risk. For over 100 years, blood pressure 
has been measured with a sphygmomanometer, which yields information about the blood pressure 
at the level of the brachial artery. This technique is slowly being superseded by the measure of 24 
hour ambulatory peripheral blood pressure, which not only negates the effects of white coat 
hypertension (BP elevation that occurs exclusively in the office setting) but also allows measurement 
of nocturnal blood pressure. Studies have demonstrated that 24 hour blood pressure monitoring is 
superior to static measures for predicting cardiovascular and all-cause mortality. 22-27  
The latest study to demonstrate this included 63,910 adults in Spain recruited over a 10 year period 
and followed up for a median period of 4.7 years.28 These patients were those who had an indication 
for ambulatory BP monitoring. At baseline, they had a mean age of 58.4yo, clinic BP of 147.9/86.7 and 
ambulatory BP of 129.2/76.5. The authors found that 24 hour systolic BP was more strongly associated 
with cardiovascular as well as all-cause mortality (HR 1.58, per 1-SD increase in pressure, 95% CI 1.56-
1.60) as compared to clinic SBP (HR 1.02, 95% CI 1.00 -1.04). 24-hour DBP, daytime SBP, night-time 
SBP and DBP were all better predictors of all cause and cardiovascular mortality than clinic BP.28 
Although these results were in support of previously published studies, the study was unique in the 
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magnitude of its cohort size but also in the fact that they classified patients into various hypertensive 
“phenotypes” that they defined such as white-coat, masked, sustained, labile, borderline, or 
refractory/resistant hypertension.  They identified those with masked hypertension (that is, those 
with normal clinic BP but elevated 24h BP) as having the highest risk and the strongest association 
with all-cause mortality (HR 2.83).  
ABPM also allows the examination of nocturnal BP dipping status. Although studies have found that 
dipping status may not be consistent in its reproducibility when repeated over time,29 multiple other 
studies have found that dipping status is associated with poorer outcomes. A meta-analysis in 3468 
patients without any baseline cardiovascular disease found that reverse dippers (ie those with an 
increase in nocturnal BP as compared with daytime BP) were at higher risk of cardiovascular disease 
than dippers, after adjustment for confounders, and independent of 24h BP.30 They also found that 
dipping status predicted all-cause mortality and CVD events (again after adjustment for confounders 
and independent of 24h BP).30 In the recent study mentioned above by Banegas et al, a post hoc 
analysis revealed that the 39.5% of patients with reduced dipping (night:day systolic BP ratio 0.9 to 1) 
had an increased risk (HR 1.17, 95% CI 1.02 to 1.34) for death from CVD with adjustment for 
demographic characteristics, cardiovascular risk factors and 24h and clinic systolic pressures.31 This 
risk increased in those with no dipping or reverse dipping (HR 1.34). 31 
Other BP variables such as BP load, BP variability and morning surge 7 have also been examined with 
regards to their predictive powers but have not been as well established as yet.  
Given the cumulative findings of the benefit of ambulatory monitoring, various national authorities 
have incorporated its use into their hypertension guidelines. The National Heart Foundation of 
Australia recommend its use in any patient with suspected hypertension, or in any patient with a clinic 
BP measurement of >=140/90mmHg for confirmation. 19  
1.2.3 Risk factors and secondary causes of hypertension 
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A number of lifestyle factors are associated with hypertension and these include obesity, weight gain, 
excess alcohol or salt intake, and certain medications.32 Some of the causes of secondary hypertension 
include obstructive sleep apnoea (discussed later), phaeochromocytoma, renal artery stenosis, and 
hyperthyroidism. Obstructive sleep apnoea is believed to be the most common cause of secondary 
hypertension,33 as well as the most common secondary cause of resistant hypertension.34   
1.2.4 Management 
 
Management of hypertension varies amongst different guidelines, although lifestyle advice is 
recommended for everyone. Generally the main consideration for commencement of anti-
hypertensives is the presence or absence of cardiovascular disease (CVD).  Australian guidelines 
recommend using the Australian absolute cardiovascular disease risk calculator (by way of an online 
algorithm at www.cvdcheck.org.au) in conjunction with the individual’s grade of hypertension.  The 
risk score categorises individuals into low (<10%), moderate (10-15%) or high risk (15%) of having a 
cardiovascular event in the following 5 years. Anti-hypertensive treatment is recommended for 
patients with a low absolute CVD risk but high BP of ≥160/100mmHg, and for patients with moderate 
or high absolute CVD risk and BP of ≥140/90mmHg.  
Treatment targets again vary between guidelines and take into consideration CVD risk, age, and the 
presence of diabetes mellitus and/or chronic kidney disease. Australian guidelines recommend aiming 
for <140/90mmHg across the board, regardless of age, however, stipulate that aiming for <120mmHg 
in those at high CVD where tolerated would be beneficial. The newest American guidelines 
recommend a BP target of <130/80mmHg across the board,20 whereas the UK NICE guidelines 
recommend a target of <140/90mmHg, but a higher threshold of <150/90mmHg in those ≥80yo.35  
1.2.4.1 Non-pharmacological management 
 
Non-pharmacological management involves salt restriction, weight loss, aerobic exercise, and 
moderation of alcohol intake. The importance of these strategies cannot be underestimated, as a 
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randomised controlled trial of patients aged 60-80yo with Grade 1 hypertension and established on 
one hypertensive, found that salt restriction and/or weight loss resulted in a reduction in systolic blood 
pressure of 3-5mmHg and diastolic blood pressure by 2-3mmHg (p<0.001 when compared to usual 
care).36  
1.2.4.2 Pharmacological management 
 
The four drug classes of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers 
(ARBs), calcium channel blockers and thiazide diuretics are all considered suitable first line anti-
hypertensives and all result in similar reductions in BP. Of all these drug classes, ACE-inhibitors and 
ARBs are the most commonly prescribed. ACE-inhibitors inhibit the formation of angiotensin II which 
is a potent vasoconstrictor. ARBs work by preventing angiotensin II from binding to its target on blood 
vessel smooth muscle, hence promoting vasodilation.  
Beta-blockers are no longer recommended as first line therapy in uncomplicated hypertension as they 
have been associated with an increased risk of diabetes, and because they have not been associated 
with favourable reductions in cardiovascular morbidity and mortality as compared with other drug 
classes.19 Beta-blockers decrease BP by reducing cardiac output, inhibiting release of renin and 
blockade of presynaptic alpha-adrenoreceptors responsible for the release of norepinephrine from 
the sympathetic nerve terminals.37 Interestingly, beta-blockers exert their effect only when the 
sympathetic nervous system is activated. 37 
In certain disease states, particular antihypertensive classes may be of greater benefit. For instance, 
in diabetes, ACE-inhibitors have been shown to delay the onset of nephropathy and to reduce 
mortality. 19  
1.2.4.2.1 Chronotherapy for hypertension 
 
There have been at least 27 chronotherapy trials in essential hypertension comparing the effects of 
morning versus evening ingestion of anti-hypertensives. The majority of these studies were performed 
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using either ACE-inhibitors or ARBs and found that PM dosing was more effective at decreasing Sleep 
BP and promoting non-dipping (SBP reduction: 4-10mmHg, DBP reduction: 2-7 mmHg, and resulted in 
anywhere between 20% - 50% more nocturnal dipping).38 However the most  important study in this 
field was the MAPEC study - a prospective study of 2156 patients with all grades of hypertension 
followed up for a mean duration of 5.6yrs.39 These patients were on any of the four classes of anti-
hypertensives, and they were randomised to have only one of their anti-hypertensives switched from 
morning to evening administration, or not. The study claimed to find that sleep SBP reduced 
substantially with PM dosing as compared with AM dosing (AM dosing -6.6mmHg, PM dosing -
11.8mmHg (p<.001)), and that PM dosing reduced the rates of unfavourable non-dipping (34% vs 62%, 
p<0.001). Importantly, this greater reduction in sleep BP from ingesting anti-hypertensives at night 
did not appear to reduce the effectiveness of daytime blood pressure control (AM dosing -9.4mmHg, 
PM dosing -8.9mmHg (NS)) nor on overall 48h SBP (AM dosing -8.6mmHg, PM dosing -9.7mmHg (NS)). 
Furthermore, the follow up period found that the relative risk of a cardiovascular event was reduced 
by 0.39 (0.29-0.51).39 There are however important limitations to this trial, the most important of 
which is that neither investigators nor patients were blinded to treatment allocation. It has been well 
established that placebo medications can lower BP significantly (up to 6mmHg in non-resistant 
hypertensives).40 41 If patients are expecting to receive a better therapeutic effect with evening dosing, 
then this magnitude of change of 6mmHg could easily bias study results.  Secondly, the study protocol 
allowed for significant heterogeneity in the anti-hypertensive management of patients. Patients could 
be on any combination of all four classes of anti-hypertensives and these were prescribed and 
amended according to the discretion of an (unblinded) physician as often as 3 monthly to improve BP 
control.   
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1.3 OBSTRUCTIVE SLEEP APNOEA 
 
1.3.1 Definition 
 
Obstructive sleep apnoea (OSA) is a condition characterised by recurrent episodes of partial 
(hypopnoeas) or complete (apnoeas) upper airway closures in sleep. These closures usually result in a 
drop in oxygen saturation and usually terminate in an arousal from sleep.  Current polysomnograph 
criteria define an apnoea as a reduction of airflow of ≥90% from baseline for ≥10 seconds based on an 
oronasal thermal sensor, whilst a hypopnoea is defined by a reduction of airflow of ≥30% from 
baseline for ≥10 seconds using the nasal pressure trace in association with either a drop in 
oxyhaemoglobin saturations of ≥3% or an arousal. 42 
The severity of OSA is based on the average frequency of apnoeas and hypopneas an hour throughout 
the night, termed the Apnoea-Hypopnea Index (AHI). An AHI ≤ 5/hour is considered normal, AHI 5-
15/hour is considered mild OSA, AHI 15-30/hr is moderate OSA, and severe OSA is an AHI ≥30/hr.  
1.3.2 Pathophysiology 
 
The pathophysiology of OSA is complex and airway occlusion or severe narrowing can occur due to a 
number of factors.43 Moreover, the relative contribution of the various factors in the pathogenesis of 
OSA is different in each patient.44 Most patients with OSA have an anatomically small upper 
(pharyngeal) airway, either because of increased soft tissue around the airway or a small bony 
enclosure45.  In addition, upper airway motor control by the pharyngeal dilator muscles may be 
reduced compared to healthy controls, resulting in a narrowing of the upper airway in sleep.44 In some 
patients, ventilatory control instability (or the ventilatory response to a change in breathing pattern) 
can predispose to upper airway obstruction. Loop gain describes the sensitivity of the ventilator 
control system to changes in breathing. A high loop gain indicates that a small change in breathing will 
translate into a corresponding large change in ventilation to correct for the physiological outcomes of 
the reduction in breathing. Patients with OSA have been found to have an elevated loop gain as 
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compared with controls, and it is thought that this ventilator instability is a key factor in the 
pathogenesis of OSA in those without a highly collapsible upper airway.44 Lastly, roughly 30% of 
patients with OSA have a low respiratory arousal threshold which means that they easily arouse from 
sleep in the event of a reduction in airflow, which then renders them more susceptible to unstable 
breathing.44 
1.3.3 Prevalence and Risk Factors 
 
A community based study of middle aged individuals that were part of the Wisconsin Cohort Study 
demonstrated  an OSA prevalence of 24% in men and 9% in women.46 However, in this cohort, “OSA 
syndrome” which includes self-reported sleepiness, affected 4% of men and 2% of women.46    
The more recent HypnoLaus community based study using the revised 2012 AASM scoring criteria 
found a much higher prevalence in their Swiss population - an AHI≥15 was found in 23% of women 
and 50% of men. 47 The findings have been mainly attributed to the use of more sensitive technology 
(nasal pressure sensors are much more sensitive in detecting hypopneas as compared to thermistors), 
as well as more relaxed scoring criteria. 47 
Risk factors for OSA are obesity, age, male gender, genetics and upper airway or craniofacial 
abnormalities.48 The prevalence of OSA increases with increasing age – increasing 2-3 fold from ages 
30- 64 years as compared to age≥65yo. 48 Similarly, the prevalence of OSA increases with increasing 
weight – a 10% increase in weight carrying a 6 times higher risk of developing OSA in those initially 
without OSA.48   
1.3.4 Management 
 
Continuous positive airway pressure (CPAP) is the most effective treatment for OSA.49 It works by 
delivering positive airway pressure to the pharyngeal airway thereby inhibiting its collapse.49 
Adherence rates are approximately 60% and factors that are associated with increased compliance 
include severe OSA and excessive daytime sleepiness.50 51  
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Other less effective therapies include mandibular advancement splints, upper airway surgery, weight 
loss, positional therapy, and lifestyle advice such as alcohol avoidance and exercise. 52 
1.4 OBSTRUCTIVE SLEEP APNOEA AND CARDIOVASCULAR DISEASE  
 
1.4.1 OSA and cardiovascular disease  
 
OSA is strongly associated with cardiovascular disease. Observational studies have found that OSA is 
associated with incident atrial fibrillation,53 stroke 54 55 and recurrent stroke,56 incident ischaemic heart 
disease, 57 and heart failure.58 A recent systematic review that included all longitudinal studies of 
adults with untreated OSA found an overall positive significant association in men for all-cause 
mortality, fatal and non-fatal cardiovascular events.59  
Repetitive episodes of intermittent arterial hypoxaemia, sympathetic activation and endothelial 
dysfunction are some of the main pathophysiological mechanisms that lead to increased 
cardiovascular morbidity and mortality. 
Although longitudinal studies have demonstrated an association, there is no strong evidence to 
demonstrate a reduction in risk with the use of CPAP. A systematic review and meta-analysis of ten 
trials including over 7000 patients did not show a reduction in acute coronary events, stroke or 
vascular death with the use of PAP therapy. 60 The largest trial in this review was the SAVE trial 
comprising over 2,700 patients.61 The reasons for the apparent ineffectiveness of PAP therapy to 
reduce cardiovascular risk are unclear. Poor compliance with CPAP has been posited as an underlying 
factor, but several authors have performed analyses that do not support this theory. 60 62 A more 
compelling explanation might be the small sample sizes of the studies. Studies with cardiovascular 
endpoints require very large sample sizes in order to detect clinically relevant reductions of event 
rates, and these sample sizes have not been achieved in the OSA population, 63 given the challenges 
associated with device-based interventions.    
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1.5 OSA AND HYPERTENSION 
 
OSA has been well established as a risk factor for the development of systemic hypertension. The 
association between sleep apnoea and hypertension has the strongest basis of all the cardiovascular 
complications. Studies of patients with essential hypertension have identified that 20-40% had 
underlying undiagnosed co-morbid OSA. 64-66  
1.5.1 Prevalence 
 
The first large cross-sectional study to demonstrate this association was the Sleep Heart Health Study 
(SHHS) which examined over 6000 middle aged to elderly individuals from the community. Patients 
underwent unattended home sleep studies. They found that the prevalence of hypertension increased 
with increasing severity of OSA. After adjusting for confounders (BMI, neck, waist-to-hip ratio, alcohol 
use and smoking), the odds ratio of having hypertension was 1.37 for those with severe OSA (AHI ≥30) 
(95% confidence interval [CI], 1.03-1.83; P= .005) as compared to those without OSA (AHI<1.5).67 The 
relationship was dose-dependent, with the odds of hypertension increasing stepwise with increasing 
AHI category.  
Subsequent to this, the same data was analysed stratified by age, and demonstrated that no 
relationship was found between AHI and the incidence of hypertension in those >60yo. In contrast, in 
those <60yo, after adjustment for confounders, AHI was significantly associated with higher odds of 
systolic/diastolic hypertension (AHI 15 to 29.9, OR=2.38 [95% CI 1.30 to 4.38]; AHI ≥30, OR=2.24 [95% 
CI 1.10 to 4.54]).68 Both studies also found a similar relationship between the odds of hypertension 
and time spent below an oxygen saturation of 90%. 
This association was replicated in the more recent HypnoLaus study, where an AHI >20/hr was 
independently associated with hypertension (OR= 1.60, 95% CI 1.14 to 2.26), after adjustment for 
confounders. 47 
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1.5.2 Incidence 
 
Although cross-sectional studies have found an association between AHI and prevalent hypertension, 
the results of longitudinal studies examining the risk of incident hypertension have been conflicting.  
The Wisconsin Sleep cohort study was a large prospective study that first demonstrated a link between 
OSA and the risk of future development of hypertension, after adjustment for confounders. They 
followed 709 patients over 4 years and found a dose-response relationship between sleep-disordered 
breathing and the incidence of hypertension (AHI 5-14.9/hr OR= 2.03 [95% CI 1.29 to 3.17]; AHI ≥15/hr 
OR= 2.89 [95% CI 1.46 to 5.64].69 
These findings were not corroborated by subsequent analysis of the follow-up data of the 
aforementioned Sleep Heart Health Study (SHHS) nor the findings of the Vitoria Sleep Cohort.70 In the 
SHHS, 2470 participants without hypertension at baseline were followed up for 5 years. Although they 
found a relationship between increasing AHI and risk of incident hypertension, this association was 
lost when adjusted for BMI. A non-statistically significant trend with incident hypertension was found 
for AHI>30. The Vitoria Sleep Cohort examined just over 1000 participants from the general 
community aged 30-70yo over 7.5years and found no association between incident hypertension and 
AHI in this cohort when adjusted for age. However, issues such as small numbers of patients with 
severe OSA in the SHHS, older age and only relatively short term follow up limit these study results. 
Additionally only baseline BMI was considered, rather than change in BMI over time which is a known 
confounder for risk of hypertension. 
In order to overcome these shortcomings, Marin et al71 set out to determine rates of incident 
hypertension amongst almost 2000 non-hypertensive patients without OSA (controls), and those with 
treated and untreated OSA over a median period of 12.2 years. They adjusted comprehensively for 
confounders, including change in weight over time and found the hazards ratio for incident 
hypertension was higher in untreated OSA as compared with controls (OSA ineligible for CPAP therapy 
HR=1.33 [95% CI, 1.01-1.75], OSA declined CPAP therapy HR=1.96 [95% CI, 1.44-2.66), non-adherent 
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to CPAP therapy HR=1.78, [95% CI, 1.23-2.58]). Additionally, the risk was lower in patients treated with 
CPAP (HR=0.71 [95% CI, 0.53-0.94]). 
1.5.3 Resistant hypertension 
 
The association between OSA and hypertension appears to be even stronger in those with resistant 
hypertension. Patients with resistant hypertension, by definition, have uncontrolled blood pressure 
(>140/90) despite lifestyle changes and the use of at least three anti-hypertensives (including a 
diuretic). 72 Studies have reported a prevalence of OSA ranging from 64% 34 to as high as 83% 73in those 
with resistant hypertension.74  
1.5.4 Non-dipping 
 
OSA has been associated with a non-dipping BP status. 16-18 This relationship has also been found to 
be longitudinal as well as related to the severity of OSA. A sub-study of 328 patients of the Wisconsin 
Sleep Cohort  found a dose-response odds of developing non-dipping with sleep-disordered breathing 
over time (OR as follows for AHI 5 to < 15 and AHI > or = 15, versus AHI < 5, were 3.1 (1.3-7.7) and 4.4 
(1.2-16.3)).18 In another sub-study of patients with cardiovascular risk factors, the authors found a 4% 
increase in the odds of non-dipping SBP for every 1 unit increase in the AHI. 75  
1.5.5 Haemodynamic consequences 
 
Upper airway occlusion leads to hypoxia, hypercapnia, large intrathoracic pressure swings, and 
arousals from sleep all of which result in increased BP. During upper airway occlusion, HR and BP 
decrease initially then increase. The resultant hypoxia induces peripheral vasoconstriction, and 
hypoxic and hypercapnic stimulation of chemoreceptors result in an increase in ventilation but also 
an increase in the sympathetic nervous system (SNS) activity.76 At the end of the apnoea with airway 
reopening and recommencement of breathing, HR increases abruptly in the setting of peripheral 
vasoconstriction, thereby causing a surge in BP.  
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Physiology studies have carefully demonstrated the acute cyclical surges in BP that occur with each 
apnoeic event. Okabe et al studied 10 men with OSA during sleep using a non-invasive Finapres blood 
pressure monitor with concurrent polysomnography.77 The mean increase in BP during apnoeaic 
episodes was an astounding 42mmHg in REM sleep and 31.9mmHg in NREM sleep.77  Interestingly 
however, subjecting the same patients to intermittent hypoxia during wakefulness did not induce such 
large BP surges, suggesting that other physiological factors contributed to BP surges in sleep in OSA. 
Arousals from sleep, for instance, which accompany the termination of many but not all apnoeic 
events, increase cardiac sympathetic activation. 
1.5.6 Pathophysiology 
 
The most important pathway by which hypertension is thought to develop in OSA is via the activation 
of the sympathetic nervous system (SNS). Patients with sleep apnoea have heightened activation of 
the SNS, not only during the night time when the parasympathetic system is meant to dominate, but 
also during the daytime as well. This leads to peripheral vascular remodelling and increased vascular 
resistance. The activation of the SNS is thought to be mediated by repetitive intermittent hypoxia from 
apnoeic episodes overnight.  As mentioned, hypoxia stimulates the chemoreceptors of the carotid 
bodies which in turn stimulate the SNS, along with ventilation, heart rate and blood pressure. Evidence 
of heightened SNS activity in OSA has been demonstrated by elevations in 24hour urinary 
catecholamines and plasma catecholamines.76  
Intermittent hypoxia (IH) is believed to cause activation of the renin-angiotensin-aldosterone system 
(RAAS). In patients with OSA, levels of angiotensin II, a potent vasoconstrictor have been found to be 
elevated,78 although kidney function, salt intake and volume status were not accounted for. 
Angiotensin II works on the type 1 Angiotensin II receptors (AT1R) located on smooth muscle cells. A 
study of 9 healthy males discovered that exposure to intermittent hypoxia resulted in an increase in 
arterial blood pressure through activation of the AT1R. 78  A more recent study in patients with OSA 
demonstrated that the severity of nocturnal hypoxaemia was associated with greater renal RAAS 
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activity, suggesting that IH was a key driving factor.79 However, this RAAS mechanism has been 
implicated more strongly in the link between OSA and resistant hypertension (RH). It is felt that 
hyperaldosteronism (and the resultant fluid overload) is the prominent underlying mechanism given 
the relatively high prevalence of primary hyperaldosteronism in patients with RH (up to 20%).80 It has 
also been found that in OSA patients with hypertension, there is greater fluid shift from the legs to 
the upper body in patients with RH as compared with drug responsive HTN.81 Similarly, an open-label 
study found that spironolactone substantially and significantly reduced the AHI in patients with OSA 
and RH, presumably through reduction of excess fluid in the upper airway.82 Lastly, it has been 
demonstrated that in patients with OSA and RH, aldosterone levels were correlated with OSA 
severity.83 All of these studies support hyperaldosteronism as a mechanistic link between OSA and RH.   
IH induces oxidative stress, or the production of reactive oxygen species, and a reduction in circulating 
nitric oxide (NO), a potent vasodilator. Although several studies have shown higher levels of markers 
such as F2-isoprostanes in patients with OSA, this has not been consistently found in other studies. 
Additionally, obesity is associated with markers of oxidative stress and may be a confounder.84 
Similarly, IH is thought to induce inflammation, with many raised inflammatory cytokines such as CRP 
and IL-6 having been found in patients with OSA. Again, these markers have also been noted to be 
raised in obesity.76 Additionally, a large RCT found no reduction in CRP with either weight loss, CPAP 
or weight loss and CPAP combined.85 
Endothelial dysfunction typically results from a lack of the nitric oxide vasodilating effect.  Several 
studies have found endothelial dysfunction is associated with OSA independent of obesity, and studies 
of treatment of OSA with CPAP have found improved endothelial function.76 
SUMMARY: The pathophysiology of hypertension in OSA is complex and not yet fully elucidated. 
However, intermittent hypoxia and over-activation of the sympathetic nervous system appear to be 
the key drivers. In resistant hypertension, there is further evidence to suggest that chronic fluid 
retention may play a key role.  
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1.5.7 Management 
 
1.5.7.1 Lifestyle changes 
 
The same lifestyle advice recommendations of salt restriction, weight loss, aerobic exercise, and 
moderation of alcohol intake given to patients with HTN apply to those with OSA and HTN. However, 
by comparison the data is limited in the OSA population.  Of note, alcohol consumption has even more 
deleterious effects in the OSA population by way of increasing the frequency and length of obstructive 
events as it reduces the arousal response and upper airway tone.86 Hence, it is particularly important 
to advise a reduction or abstinence in OSA patients.   
Additionally, weight loss in OSA has been shown to reduce BP. Chirinos et al performed a randomised 
controlled trial to determine whether CPAP alone, weight loss alone or combined treatment improved 
CRP levels in patients with moderate to severe OSA.85 Office BP was an exploratory endpoint. Patients 
with BP>160/95 mmHg were excluded and at baseline 40% of patients were taking ant-hypertensives. 
After 6 months of treatment, they found that all treatment modalities resulted in significant 
reductions in BP but were equivocal in their efficacy (CPAP alone – 4.2mmHg, Weight loss and CPAP -
7.8mmHg, weight loss alone -5.1mmHg). However, in a per-protocol population of 90 patients 
adherent to CPAP for more than 4 hours a night for 70% of the study period, as well as having lost at 
least 5% body weight, the authors found that combined CPAP and weight loss was significantly more 
effective at reducing BP (by -14.1mmHg (CI -18.7mmHg to -9.5)) as compared to either treatment 
alone. Importantly, weight loss was just as effective as CPAP in reducing BP (-6.8mmHg vs -3mmHg 
respectively, p=0.16).  
A small observational study showed that weight loss through a very-low calorie diet in patients with 
OSA reduced the severity of OSA as well inducing significant reductions in office blood pressure.87 
Another study of 60 patients looked specifically in hypertensive OSA patients and found that weight 
loss alone was more effective in significantly reducing BP than nasal CPAP or combined therapy.88  
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SUMMARY: These studies highlight the importance of weight loss in the management of patients 
with OSA and HTN either as stand-alone therapy or in concert with CPAP.  
1.5.7.2 Device based therapies 
 
Although mandibular advancement splints (MAS) are considered less effective in controlling OSA as 
compared with gold standard CPAP, a recent systematic review and meta-analysis of RCTs specifically 
examined its effect on reducing blood pressure.89 Interestingly, they found that MAS devices and CPAP 
were both associated with similar reductions in SBP and DBP, when compared with inactive controls.89  
Multiple meta-analyses of RCTs have demonstrated that CPAP results in a modest reduction in SBP of 
approximately 2-3mmHg.90 91 92-94 The largest and most recent of these was performed by Fava et al , 
and included 31 studies that measured office and/or ambulatory BP in a total of 1820 subjects. Overall 
CPAP reduced office SBP and DBP by -2.6mmHg and -2.0mmHg respectively (p<0.001). Ambulatory 
blood pressure monitoring (n=14 studies) demonstrated a reduction of daytime SBP by -2.2mHg and 
DBP by -1.9mmHg, and night-time values of SBP by -3.8mmHg and DBP by -1.8mmHg.  In sub-analyses, 
the reductions in BP were not significant in studies where patients had mild to moderate OSA (AHI<30) 
and where they were not hypersomnolent (ESS<10), and possibly in those with lower CPAP adherence, 
although this has not been corroborated in all the meta-analyses. An important observation was that 
CPAP on its own was not sufficient to normalise BP.  
Larger reductions in BP have been demonstrated with the use of CPAP in patients with resistant 
hypertension (RH) and OSA. A previous meta-analysis in 2014 examining the role of CPAP in reducing 
BP in patients with OSA and resistant hypertension found from the pooled estimates of the four RCTs 
available that CPAP reduced 24hr SBP and DBP by -6.74mmHg (95% CI -9.98 to -3.49, p<0.0001) and -
5.94mmHg (95% CI -9.40 to -2.47, p<0.0001) respectively.95 However, one of these studies was only 3 
weeks long and only measured office BP. A more recent meta- analysis which did not include this 
study, and instead included a more recent and the only sham-controlled double blinded interventional 
study demonstrated overall less impressive changes in 24h SBP and DBP of -4.78mmHg (95% CI -7.95 
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to -1.61) and -2.95mmHg (95%CI -5.37 to -0.53) respectively in those on CPAP.96 These changes are 
still more than two-fold greater than those seen in OSA patients without resistant hypertension.  
Surprisingly, both meta-analyses found no significant reduction in nocturnal SBP with CPAP, although 
the most recent and up-to-date meta-analysis found that nocturnal DBP reduced by -1.53mmHg (95% 
CI, -3.07 to 0). 96 
Recognition of the high prevalence of RH in patients with OSA, as well as the significant change in 
24hour SBP and DBP that can be achieved with the addition of CPAP has prompted many guidelines 
to recommend screening for OSA in those with RH. This is particularly in light of the fact that patients 
with RH (with or without OSA) have a 50% higher odds of a cardiovascular event and target organ 
damage compared to controlled hypertensives (HR 1.47 (95%CI 1.33 – 1.62).97   
1.5.7.3 Pharmacotherapy with anti-hypertensives in OSA 
 
In contrast to CPAP intervention trials, the effect of anti-hypertensives on blood pressure in patients 
with OSA is much more impressive, with studies demonstrating reductions in SBP of anywhere 
between 4 to 24mmHg depending on the antihypertensive agent(s) used and the dose.98 Only one 
study has compared CPAP directly with an antihypertensive agent.99 Pepin et al performed a crossover 
RCT studying 23 patients with hypertension and OSA, and treated them with either Valsartan alone or 
CPAP therapy for 8 weeks. In terms of 24 hour SBP/DBP, CPAP alone resulted in a significant reduction 
of -2.1 +/- 4.9 mmHg (p <0.01), whilst Valsartan alone caused a much larger reduction of -9.1 +/- 7.2 
mmHg (p <0.001) (difference of -7.0 mm Hg [95% CI: -10.9 to -3.1 mm Hg; p<0.001]). In terms of night-
time SBP/DBP, CPAP alone made no significant difference -1.3 +/- 4.6 mm Hg (NS), whilst Valsartan 
alone caused a reduction of -7.4 +/- 8.4 mm Hg (p <0.001) (difference of -6.1 mm Hg (p<0.05) [95% CI, 
-10.8 to -1.4 mm Hg]). Although the BP decrease was significant with CPAP treatment for overall 24h 
BP, valsartan induced a four-fold higher decrease than CPAP in untreated hypertensive patients. 
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In a review by Diogo et al, 12 RCTs were presented of various antihypertensives used for the treatment 
of hypertension and OSA.98 The most important observation was that no one drug class/agent was 
shown to be particularly more effective. Ten of the studies employed ambulatory blood pressure 
monitoring (ABPM) and in one study the beta-blocker atenolol was more beneficial 100, potentially in 
keeping with anti-sympathetic effects. However, sympatholytic agents such as beta blockers are not 
recommended as an initial antihypertensive because they have been linked with poor health 
outcomes.101 Other important points from the pharmacotherapy studies are that many of the RCTs 
had small sample sizes and drug doses were not necessarily therapeutically equivalent. Based on the 
available studies, no particular drug class can be specifically recommended as superior for the 
treatment of hypertension in OSA and this is reflected in the published guidelines.86 102 Future 
pharmacotherapy trials will at a minimum, require larger sample sizes to be adequately powered, and 
will need to use equivalent drug doses.  
 An important but simple question that has only been explored by one study thus far is whether 
antihypertensives exert the same effects in patients with and without sleep apnoea. Thunstrom et al 
performed a case control study of patients with newly diagnosed hypertension with and without OSA 
and treated them with Losartan 50mg daily for 6 weeks.103 Even though the OSA group were not 
particularly severe (mean AHI of 18.4events/hr and ODI of 8.5events/hr), those with OSA 
demonstrated a “blunted” response (those with OSA – 24h SBP reduced by 9.8mmHg, those without 
OSA – 24h SBP reduced by 12.6mmHg).  
Assuming that OSA is the main driving force for HTN in this cohort, it is prudent to recognise that anti-
hypertensives are not treating the root cause, but rather addressing the consequences. CPAP therapy, 
on the other hand, would serve to eliminate the pathophysiological triggers leading to HTN. 
1.5.7.4 Combination of CPAP and pharmacotherapy 
 
In clinical practice, the standard approach for treating HTN in OSA involves a combination of lifestyle 
changes, pharmacotherapy, and CPAP therapy. Whether the addition of CPAP to pharmacotherapy 
24 
 
results in a synergistic or additive effect was explored in a cross-over RCT.104  Fourty-four patients with 
Stage 2-3 hypertension and severe OSA were commenced on triple anti-hypertensive therapy, after 
which they were randomised to either sham CPAP or CPAP. The anti-hypertensives alone reduced 24h 
BP dramatically (SBP decreased by 25.4 ± 12.1 mmHg and DBP by 11.6 ± 2.0 mmHg) and adding CPAP 
reduced 24h BP even further  SBP −5.8 ± 1.0 mmHg (p = 0.05) and DBP −4.5 ± 0.5 mmHg (p = 0.04).104 
Importantly this effect was not observed with sham CPAP and compliance was very good at 5.1 ± 1.6 
hours.104 On the other hand, Thumstrom et al (n=47) found no additive effect with CPAP on their 
primary outcome of 24h BP, but did find a reduction in sleep BP of 4.7mmHg (p= 0.021).103 The 
important distinction between these two studies is the severity of the hypertension and of the sleep 
apnoea, and the use of sham CPAP. 
Lozano et al105 looked specifically at patients with resistant hypertension and OSA in a parallel RCT of 
75 patients, comparing patients on three anti-hypertensives alone versus three anti-hypertensives 
and the addition of CPAP. The addition of CPAP only resulted in a decrease in 24h DBP (-4.9 ± 6.4 vs. 
0.1 ± 7.3 mmHg, P = 0.027) and not SBP. However, when they performed a subgroup analysis of those 
with high CPAP compliance (>=5.8hrs/night), they found that the group with the double intervention 
had a greater reduction in daytime diastolic BP,105 24-h diastolic BP (-6.98 mmHg [CI -1.86; -12.1], P = 
0.009), 24-h systolic BP (-9.71 mmHg [CI -0.20; -19.22], P = 0.046) and that the number of patients 
with a dipping pattern significantly increased in the CPAP group (51.7% vs. 24.1%, P = 0.008). 
SUMMARY: These data suggest that stand alone pharmacotherapy for hypertension in OSA is very 
efficacious, but that the addition of CPAP therapy may enhance its efficacy and should be added to 
the treatment regimen where tolerated as there appears to be an additive effect. This effect is most 
notable in those with resistant hypertension. 
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1.6 RATIONALE FOR CHRONOTHERAPY FOR HYPERTENSION IN OBSTRUCTIVE SLEEP 
APNOEA 
 
A strong association exists between OSA and hypertension, and hypertensive patients with OSA 
represent a vulnerable group, at higher risk of cardiovascular morbidity and mortality. Observations 
of BP profiles over 24 hours have revealed the prognostic importance of nocturnal BP, and subjects 
with OSA demonstrate high rates of nocturnal hypertension and non-dipping, presumably due to 
excessive sympathetic discharge. 
Given the underlying physiological differences in individuals with OSA with regards to hypertension as 
compared with those with essential hypertension, a dedicated management approach is essential. 
Thus far, we have observed the shortcomings of stand-alone therapy with CPAP, and we note that 
anti-hypertensives appear to have a dampened effect in OSA.    
A large number of studies have demonstrated the effectiveness of chronotherapy in hypertension by 
reducing nocturnal BP in patients with essential hypertension, simply through changing the ingestion 
of once-daily anti-hypertensives from morning to evening. A large longitudinal study has even shown 
relative risk reduction in cardiovascular events over a 5 year period. This simple, cost-free 
chronotherapeutic approach appears highly pertinent to OSA and could represent the novel strategy 
needed in improving hypertension control in this vulnerable group.  
In the first study of this thesis (presented below), we undertook the first chronotherapy randomised 
controlled trial in OSA. To ensure the reliability of our results, we designed it as a robust double blinded 
placebo controlled RCT. In so doing, our study represents the only double-blinded placebo controlled 
chronotherapy trial in any population to date.   
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1.7 CENTRAL BLOOD PRESSURE AND MEASURES OF WAVE REFLECTION 
 
Although peripheral BP has been the standard tool used in the clinical setting to stratify future 
cardiovascular risk or to monitor clinical efficacy of anti-hypertensives, newer studies are 
demonstrating that non-invasively measured central BP might deliver more accurate prognostic and 
therapeutic information.   
Central BP refers to the pressure at the level of the aorta, and a more accurate reflection of the 
pressure exerted on the heart and target organs. The gold standard/most direct measurement of 
central BP is through cardiac catheterization, with the insertion of a pressure transducer at the level 
of the ascending aorta. This is a highly invasive procedure with associated risks. More recently, a non-
invasive technique called Pulse Wave Analysis (PWA) has been developed, which involves capturing 
pressure waveforms from peripheral arteries such as at the level of the brachial or radial artery. These 
pressure waveforms are then used to estimate central BP using a generalised transfer function or by 
a proprietary algorithm. 
Analysis of this pressure waveform allows the measurement of other useful indices of arterial 
haemodyamics. As the heart contracts, it pushes blood through the aortic valve into the aorta. From 
here the pressure wave travels down the descending aorta and out to the peripheral arteries in the 
systemic circulation. The shape of this pressure waveform changes as it moves from large-diameter 
central to small-diameter distal sites, and systolic pressure gradually increases. This increase in 
pressure, also known as pulse pressure amplification, is due to a progressive increase in resistance as 
the pressure waveform moves to the smaller less elastic peripheral arteries. The aortic pulse pressure 
waveform is generated not only by the forward moving pressure wave but also from reflected pressure 
waves that return after encountering impedance at bifurcation sites, or when arterial stiffness or 
width changes.  These reflected waves then augment the incident pressure waveform, contributing to 
the final aortic systolic pressure. The difference between systolic pressure and diastolic pressure is 
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termed pulse pressure. Augmentation index (AIx) is the proportion of pulse pressure that is accounted 
for by the augmentation pressure.  It serves as a surrogate measure of systemic arterial stiffness.  
However, the gold standard technique of measuring arterial stiffness is performed using Pulse Wave 
Velocity (PWV). This technique measures the speed at which a pulse pressure waveform travels down 
a segment of an artery.106 An important distinction between PWV and AIx as measures of arterial 
stiffness is that PWV is examining the arterial stiffness in one particular segment of artery, whereas 
AIx is more a measure of wave reflection due to the properties of the vascular tree.106     
1.7.1 Non-invasive measurement techniques 
 
Pulse wave analysis can be applied to pressure waveforms obtained at the brachial or radial arteries, 
and then calibrated to blood pressure obtained by cuff sphygmamonometry.107 Older devices obtained 
the pressure waveform through applanation tonometry, which involved placing a pen-like high-fidelity 
pressure transducer on the skin overlying the radial artery and capturing waveforms. This technique 
has several disadvantages. Firstly, it is very operator dependent but secondly, the waveforms are 
calibrated against blood pressure derived from the brachial cuff sphygmomanometer, which does not 
take into account the further rise in systolic BP which would be present radially (brachial-radial 
“amplification”). 
The most recent technology uses waveforms obtained oscillometrically with a brachial cuff, by 
measuring the oscillations created in the cuff as blood pressure is being measured. This technique is 
much less operator dependent and obliterates any concerns of brachial-radial amplification.   
1.7.2 Prognostic and therapeutic implications of central BP 
 
There is emerging evidence to support the new technique of non-invasive central BP measurement. 
In an effort to explore the superiority of central BP from a physiological standpoint, a meta-analysis of 
cross-sectional studies examined the association between non-invasive central BP and peripheral BP 
and target-organ damage (TOD).108 TOD refers to microvascular and macrovascular damage that 
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occurs as a result of persistent hypertension. Left ventricular mass/hypertrophy (LVH) is the most 
widely accepted marker of cardiac damage related to hypertension. The results demonstrated that 
central BP was more closely associated with left ventricular mass index and carotid intima media 
thickness than peripheral BP in >6000 participants. This supports the hypothesis that central BP better 
reflects the haemodynamic stress exerted on target organs.108 Notably, the studies examined static 
measures of central BP with the radial tonometry technique.  
More recent studies have used 24 hour cuff-based oscillometric ambulatory measures of central BP 
to determine whether 24 hour central BP is a better predictor than 24 hour peripheral BP, of left 
ventricular mass and left ventricular hypertrophy given the cumulative effect on systolic load. 109 110 
111 In comparison to 24 hour peripheral BP, one of the studies (n=230) found that 24hour central BP 
was superior in its association with LVH, 111 whilst another study (n=289) found a strong trend towards 
a closer association with LVH. 109 In contrast, a third study (n= 208) found 24hour central BP was not 
better associated with TOD than 24 hour peripheral BP.110 Although they all used the same Mobil-O-
Graph device, the second study only found a stronger association with central BP using a different 
(mean BP/diastolic BP) calibration method. The final opposing study defined TOD as the presence of 
either LVH, renal organ damage or aortic stiffness, rather than LVH alone, hence the results are not 
directly comparable. Overall, it still remains unclear whether central BP is superior to peripheral BP in 
predicting target organ damage.  
Several studies in specific subgroups of patients such as those with end-stage renal disease, ischaemic 
heart disease, and advanced age, have suggested that static measures of non-invasive central BP are 
a better prognostic indicator than peripheral BP. 112-114 115 The potential prognostic value for 
cardiovascular outcomes and all-cause mortality of central BP was studied in a meta-analysis of 11 
longitudinal studies.116 Almost 6000 participants were followed up for a mean period of 45months.   
The results found that central BP, pulse pressure (PP) and central augmentation index (AIx) were all 
independent predictors of future CV events and AIx was an independent predictor of all-cause 
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mortality.  They concluded that an increase in C_SBP of 10mmHg corresponded to an 8.8% increased 
risk of cardiovascular events and that a 10% increase in AIx translated to a 32% increased risk of 
cardiovascular events and a 38% increase in mortality. Central PP was a slightly better predictor of 
cardiovascular events as compared with peripheral PP [1.318 (95% CI 1.221–1.423) vs. 1.188 (95% CI 
1.104 –1.280) respectively], but this did not reach statistical significance (p=0.057). 116 As yet, given 
the newness of the technology, there are no studies using 24 hour ambulatory central BP 
measurements to assess the prognostic value for cardiovascular mortality and morbidity.  
Finally, anti-hypertensives appear to exert differential effects on central and peripheral BP. The first 
pivotal study to demonstrate this was the 2006 Conduit Artery Function Evaluation (CAFÉ) study.117 
Since then, a meta- analysis of over 50 studies has shown that anti-hypertensives reduce peripheral 
SBP more than central SBP (by 2.52 mm Hg, 95% CI 1.35 to 3.69) and this difference is similar across 
all drug classes (ACE-Is, ARBs, CCBs, diuretics, and RAAS-Is) except for beta blockers which reduce 
peripheral BP significantly more than central BP.118 Furthermore, ACE-Is, ARBs, CCBs, diuretics and 
RAAS-Is, all significantly reduce AIx whilst Beta-blockers and some other specific anti-hypertensives 
do not.  This discovery could explain why Beta-blockers have been inferior in preventing cardiovascular 
events.118 Whilst these studies were all conducted in populations where OSA was not specifically 
identified, it does lead us to question whether the same principles apply to hypertensive patients with 
OSA, and whether (like anti-hypertensives), CPAP therapy also has differential impacts on central and 
peripheral BP.  
Summary:  Central BP is the pressure at the level of the aorta, and better reflects the true 
haemodynamic load on target organs. Central BP can now be measured non-invasively as well as 
over 24 hours. There is accumulating evidence that central BP may be more strongly associated with 
target organ damage and a better prognostic indicator than peripheral BP. 
  
30 
 
1.8 CENTRAL BLOOD PRESSURE, MEASURES OF WAVE REFLECTION AND OSA 
 
A large number of studies have reported a positive association between OSA and measures of arterial 
stiffness.106 Whether this association is causal in nature has yet to be determined, with some but not 
all RCTS showing that CPAP reduces measures of arterial stiffness.106 However, a recent rigorous meta-
analysis of individual data of patients with OSA and the gold-standard PWV-measured arterial stiffness 
found no association.119   This cross-sectional analysis suggests that the static (or fixed) arterial 
stiffness related to collagen/elastin composition of arteries is unaltered in OSA patients. 
Using single time-point measures, Phillips et al found that the AIx was positively correlated with OSA 
severity and was higher in the morning compared to the evening. Central BP was also higher in the 
morning than in the evening, whilst peripheral BP remained unchanged. 120 This study provided the 
first insight into the potential disparity between peripheral and central BP readings as well as into the 
potential dynamic diurnal variation in central BP and AIx in the OSA population.  
Over the last few years, studies have described for the first time, the diurnal variation in central BP 
and measures of arterial stiffness over 24 hours in the normal population in hypertensive and 
normotensive populations without OSA. 115 121-123 What has been consistently observed is that central 
BP and peripheral BP behave differently, in that sleep reductions in central BP are attenuated as 
compared with peripheral BP. Furthermore, a greater sleep reduction in peripheral pulse pressure 
occurs as compared with central pulse pressure, leading to a decrease in pulse pressure amplification. 
115 122-124 
 To date, there has been only one study examining “arterial stiffness” in normotensive OSA patients 
over a 24 hour period.125 Unfortunately, several aspects of the study, including the methodology, raise 
concerns about its reliability.  In the control group, the AIx dropped significantly from daytime to night-
time, whereas in the OSA subjects there was a lack of overnight reduction.125 This result in itself is 
contrary to multiple much larger studies that have all documented increases in AIx overnight in both 
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hypertensives and normotensives non-OSA populations.123 124 126 Additionally, the authors did not 
report on central BP values, nor did they examine any pre and post CPAP changes.   
1.9 RATIONALE FOR 24 HOUR CENTRAL BLOOD PRESSURE MONITORING IN OSA  
 
The OSA population clearly have a different underlying physiology over 24 hours, with increased non-
dipping and increased sympathetic discharge in sleep. So many unanswered questions still exist about 
the physiology underlying hypertensive OSA patients. We are unable to explain definitively why 
patients with OSA are inherently more difficult to treat and more vulnerable.  If it were simply a case 
of abolishing the underlying OSA, then we are as yet unable to explain why the use of CPAP confers 
only modest reductions in BP and no significant reductions in cardiovascular risk.  We require new 
biomarkers to assess risk in this population. Assessing central BP and markers of arterial stiffness over 
24 hours could provide us with valuable insights. Does CPAP affect peripheral BP differently to central 
BP, providing the illusion of ineffectiveness when measured peripherally? How do different anti-
hypertensives affect central BP in patients with OSA? In the second study of this thesis we examine 24 
hour central BP and measures of arterial stiffness for the first time in patients with OSA.  
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2.1 CHRONOTHERAPY FOR HYPERTENSION IN OBSTRUCTIVE SLEEP APNOEA 
 
In the previous section, we detailed the evidence for the effectiveness of chronotherapy for 
hypertension in essential hypertensives. This simple and cost-free strategy of changing medication 
ingestion times could result in significant improvement in the management of patients with OSA and 
hypertension. Herein, we present the first chronotherapy randomised controlled trial in OSA, designed 
as a robust double blinded placebo controlled cross over trial to address the previously described 
limitations of placebo effects related to the lack of blinding. Our study represents the only double-
blinded placebo controlled chronotherapy trial in any population to date.   
The following manuscript was published in Thorax with an accompanying editorial. It was also 
awarded The University of Sydney’s Deans Publication Prize 2017, the New Investigator Award at the 
Australasian Sleep Association Prize 2015, and the International Trainee Scholarship Award from 
American Thoracic Society 2016. 
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2.2 SUPPLEMENT 
 
Online Data Supplement  
Chronotherapy for Hypertension in Obstructive Sleep Apnoea (CHOSA): 
A Randomised, Double-blind, Placebo Controlled Crossover Trial 
Yasmina Serinel, Brendon J Yee, , Ronald R Grunstein, Keith H Wong, Peter A Cistulli,  Hisatomi Arima, 
Craig L Phillips  
Methods 
Recruitment 
Recruitment was stopped after 79 patients had completed the second treatment phase (96% of target) 
because grant funding had finished. The trial was stopped when these patients had completed the 
entire study.     
Exclusion criteria 
Additional exclusion criteria were: intolerance to Angiotensin Converting Enzyme Inhibitor (ACE-i) 
medications, shift workers who rotate to night shift, patients unwilling to undergo washout of ACE-i 
or Angiotensin Receptor Blocker (ARB) medication, poorly controlled diabetes (defined as HbA1c≥8), 
unstable angina, heart failure NYHA Class III and IV, recent (<6 months) revascularisation procedure 
or AMI, significant arrhythmia or atrial fibrillation, chronic kidney disease, more than 20% of AHI with 
central apneas, cognitive impairment, uncontrolled psychiatric disorders or physically unable to 
participate in the study. 
Sleep studies 
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Sleep studies were performed across various centres using different polysomnography equipment but 
with similar scoring criteria.  Patients were recruited from 2011 to 2015 which incorporates the change 
in recommended AASM scoring criteria in 2012.1 Throughout the trial the oxygen desaturation index, 
our main PSG qualifying criteria, was based on a desaturation of ≥3% that followed a hypopnea or an 
apnoea.   
Run-in phase 
Patients not previously on an ACE-inhibitor or ARB underwent a 4 week run-in phase (5mg perindopril 
for the first two weeks followed by 10mg perindopril for two weeks). Patients previously on ACE-
inhibitor underwent a one week run-in phase (10mg perindopril) whilst patients on an ARB underwent 
a two week run-in phase (10mg perindopril). Renal function was monitored during this phase and 
patients with deterioration in renal function were withdrawn.   
Actigraphy analysis 
Patients were asked to wear an actiwatch for 24hours, in conjunction with the 24 hour Ambulatory 
blood pressure monitoring (ABPM). Actiwatches were configured to collect activity and light at 15 
second epochs. Actigraphy data was analysed manually using Actiware (Phillips Actiware v.6, 
Respironics Inc, Murrysville PA, USA). The data were analysed by one investigator using a combination 
of the patient’s sleep diary, reported sleep and wake times, and the data available from the actiwatch 
download. If these were inconsistent, a second experienced scorer was consulted for an independent 
analysis and consensus was obtained. Sleep onset and offset times were marked on the actogram, 
including naps during the day-time, and wakeful periods during the night. Hence a sleep period was 
not always a continuous period throughout the night. This allowed us to accurately identify sleep and 
wake times.  
The actiware options and settings were as follows: 1. wake threshold selection was set at medium, 2. 
immobile minutes for sleep onset and sleep end were set at 10 minutes. However, some patients 
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demonstrated very frequent movements during sleep and in these patients the immobile minutes 
setting was reduced to zero minutes in order for the software to recognise the period as sleep. Based 
on the results of the analysed actogram, the investigator then assigned a status of either wake or sleep 
to each blood pressure recording taken over the 24 hour period.  
Measurement of blood pressure 
Office blood pressure readings were performed manually using the Mercury-Free 
Sphygmomanometer UM-101 (A&D, Tokyo, Japan) and according to EHS guidelines.2  
Ambulatory blood pressure monitoring 
The machine was set to take 30 minutely readings during the day and hourly readings overnight based 
on anticipated sleep times according to the patient. If the proportion of successful readings was lower 
than 80%, the patient was asked to repeat the test. If the patient did not consent to repeat the test, 
the initial 24hr recording was utilised as per intention to treat. Technique was otherwise as per the 
EHS guidelines.3 
Medications  
Medications, both active and placebo were provided by the pharmaceutical company, Servier 
Laboratories (Australia).  Packaging according to randomisation number and treatment arm was 
completed by Pharmaceutical Packaging Professionals.  The medication, perindopril arginine 
(Coversyl) was provided in 5mg tablets.  The active and placebo medications were identical in 
appearance and quantity. CPAP machines and settings  
Patients were contacted by the CPAP therapist one to two weeks after commencing CPAP to ensure 
that there were no issues with acclimatisation. If the CPAP therapist was concerned, the patient was 
reviewed face-to-face with potential change of machine and pressures to optimise control of OSA and 
patient comfort. To this effect, two patients were changed from the standard fixed pressure to an 
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auto-setting machine. At the end of the 8 week period, machines were downloaded to obtain usage 
and residual AHI data. 
Results 
24h-ABPM and actigraphy data quality 
There were 324 24h-ABPM recordings analysed with an average of 87% successful blood pressure 
readings. This far exceeded the current recommendation of at least 70% of readings.3 There were no 
missing 24h blood pressure data unless the patient had withdrawn. 
Of the 322 actiwatch recordings, 20 (6%) were found to be unsuccessful and self-reported sleep-wake 
times were used to determine sleep-wake periods for 24h ABPM. 
Weight 
There was no change in weight in patients from baseline to either morning or evening dosing. However 
there was a significant change in weight when CPAP was added to those on the morning active dose 
(-0.57kg +/-1.6 SD, p=0.03). This contrasts with a non-significant reduction in weight in patients on an 
evening dose (-0.63kg +/- 1.9 SD, p=0.06), although there was no significant difference in the change 
in weight between the two groups (-0.07kg, p=0.90). 
Medication compliance 
Medication compliance was calculated by pill counts from returned bottles. If the bottles were not 
returned, the data was considered missing. This occurred for 141/1644 (8.6%) of bottles. Overall 
compliance was over 90% across all treatment phases and regardless of whether the medication was 
active or placebo. However, patients tended to be more compliant with morning medications. In 
phase 1, patients took evening active tablets less than morning placebo tablets (95.8% vs 97.6%, 
p=0.038), and took morning active tablets more often than evening placebo tablets (97.2% vs 93.8%, 
p=0.002). In phase 2, patients took evening active tablets less than morning placebo tablets (90.9% vs 
96%, p=0.016), but took morning active tablets equally to evening placebo tablets (96.7% vs 96.5%, 
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p=0.92). Patients who started in phase 1 with morning active tablet dosing then had evening active 
tablet dosing in the phase 2 were less compliant with evening dosing in the second arm (97% vs 91%, 
p=0.013). There was no difference in compliance in those that started with evening active tablets in 
the phase 1 then had morning active tablets in phase 2 (94.5% vs 98.6%, p=0.13). In phase 3, patients 
were equally compliant with either morning or evening active tablets (95.3% vs 94.6% respectively, 
p=0.80).  
CPAP data 
CPAP compliance failed to be initially obtained from one patient’s device due to a technical issue and 
this patient was asked to repeat testing for a further 24 hours with CPAP and 24 hour blood pressure 
monitoring together. The compliance data obtained from this patient was hence from only one nights 
recording rather than the eight week period. Two patients did not use their machine during the entire 
allocated period and hence residual AHI data was unavailable. 
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Figure E1. Ambulatory blood pressure profiles for patients at baseline, after morning or evening 
dosing for six weeks, and after the addition of CPAP for eight weeks.  
The top panel shows systolic blood pressure (SBP) over 24 hours for the group of patients from 
baseline that ultimately completed the study on morning (AM) dosing and CPAP.   It does not include 
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their response to PM dosing. The bottom panel shows similar results for patients from baseline that 
ultimately completed the study on evening (PM) dosing and CPAP. It does not include their response 
to AM dosing.  
 
Table E1. Office blood pressure results before and after treatment with morning and evening dosing 
of perindopril (n=80)* 
 
Variable AM dosing PM dosing Difference 
between 
groups† 
P value for 
difference 
between groups 
Office SBP, 
mmHg 
136.1 ± 1.3 136.1 ± 1.2 -0.02 
(-1.9 to 1.8) 
0.986 
Office DBP, 
mmHg 
86.9 ± 1.0 88.8 ± 1.0 1.9 
(0.0 to 3.7) 
0.046 
*Values are means ± standard error. Analyses performed using paired samples t-test 
†Refers to “PM dosing” – “AM dosing” 
SBP- Systolic blood pressure, DBP – Diastolic blood pressure, AM – morning dosing; PM – evening 
dosing 
 
 
 
Table E2. Office blood pressure results before and after addition of CPAP to either morning or 
evening dosing of perindopril* 
 
Variable AM dosing and 
CPAP (n=39) 
PM dosing and 
CPAP (n=38) 
Difference 
between 
groups† 
 
P value for 
difference 
between 
groups 
Office SBP, mmHg 136.2 ± 2.2 137.6 ± 1.8 1.4 
(-4.3 to 7.0) 
0.63 
Office DBP, mmHg 85.1 ± 1.9 87.0 ± 1.4 1.8 
(-2.8 to 6.5) 
0.43 
*Values are means ± standard error. Analyses performed using independent samples t-test 
†Refers to “PM dosing and CPAP” – “AM dosing and CPAP” 
SBP- Systolic blood pressure, DBP – Diastolic blood pressure, AM – morning dosing; PM – evening 
dosing, CPAP – Continuous positive airway pressure. 
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Table E3. Sub-group analysis of non-dippers before and after treatment with morning and evening perindopril (n=21)* 
Variable Baseline AM dosing Change from 
baseline to 
AM dosing 
(95% CI) 
P value 
for 
change 
PM dosing Change from 
baseline to PM 
dosing 
(95% CI) 
P value 
for 
change 
Difference 
between 
groups† 
(95% CI) 
P value for 
group 
comparison† 
Wake mean SBP, mmHg 146.5 ±  2.7 135.8 ±  2.7 -10.7 
(-12.1 to -9.2) 
<0.001 139.9 ± 2.7 -6.6 
(-8.0 to -5.2) 
<0.001 4.1 
(2.7 to 5.5) 
<0.001 
Sleep mean SBP, mmHg 139.2  ± 2.8 127.0  ± 2.7 -12.3 
(-15.3 to -9.3) 
<0.001 127.8  ± 2.7 -11.5 
(-14.5 to -8.5) 
<0.001 0.8 
(-1.9 to 3.5) 
0.57 
24-h mean SBP, mmHg 145.1 ±  2.6 133.9 ±  2.6 -11.1 
(-12.5 to -9.8) 
<0.001 137.0 ±  2.6 -8.1 
(-9.4 to -6.7) 
<0.001 3.0 
(1.7 to 4.4) 
<0.001 
Wake mean DBP, mmHg 91.1 ±  2.0 84.9 ± 2.0 -6.2 
(-7.2 to -5.2) 
<0.001 87.6 ± 2.0 -3.5 
(-4.5 to -2.5) 
<0.001 2.7 
(1.7 to 3.6) 
<0.001 
Sleep mean DBP, mmHg 83.0 ±  1.9 77.9  ± 1.9 -5.1 
(-7.3 to -2.9) 
<0.001 77.9  ± 1.9 -5.1 
(-7.3 to -2.9) 
<0.001 0.0 
(-2.0 to 2.0) 
1.00 
24-h mean DBP, mmHg 89.5 ±  1.9 83.4 ± 1.9 -6.1 
(-7.1 to -5.1) 
<0.001 85.3 ± 1.9 -4.2 
(-5.1 to -3.2) 
<0.001 1.9 
(1.0 to 2.9) 
<0.001 
*Plus-minus values are means ± standard error. SBP- Systolic blood pressure, DBP – Diastolic blood pressure, AM – morning dosing; PM – evening dosing 
†Refers to “Change from baseline to PM dosing” – “Change from baseline to AM dosing”
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2.3 EDITORIAL 
 
The following pages contain the editorial that accompanied the publication. 
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3 CHAPTER THREE 
 
In this chapter we present a study which examines the 24 hour diurnal variation in central blood 
pressure in patients with OSA. This manuscript was submitted to the Journal of American Society of 
Hypertension. It underwent peer review and we received positive feedback from the reviewers with 
helpful suggestions. Our revised manuscript had been under review for a month. We enclose herein 
the revised manuscript in the form in which it was submitted and under review. 
As discussed in the previous section, recent literature suggests that central blood pressure (BP) and 
pulse pressure amplification (PPA) may be superior predictors of future cardiovascular events than 
peripheral BP. Furthermore, anti-hypertensives have been shown to affect central BP differently to 
peripheral BP. Advances in technology now allow the non-invasive measurement of 24 hour 
ambulatory central BP and PPA. In this study we characterise for the first time the diurnal profile of 
central BP and PPA in patients with obstructive sleep apnoea (OSA). We found that central and 
peripheral BP behaved differently across the 24 hours. During sleep, peripheral pulse pressure (PP) 
narrowed, whereas central PP did not, resulting in a decreased PPA. This novel study provides a new 
direction for future research to better understand arterial haemodynamics and cardiovascular risk 
stratification in OSA, a group in which hypertension is difficult to control. 
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3.1.1 Abstract 
 
Study Objectives: 
Recent evidence suggests that compared to peripheral blood pressure (BP), central BP may be more 
strongly associated with target organ damage and cardiovascular morbidity and mortality. 
Technological advances now allow the ambulatory measurement of peripheral and central BP over 24 
hours. For the first time, we set out to characterise the diurnal profile of central BP and pulse pressure 
amplification (PPA) in patients with obstructive sleep apnoea (OSA).  
Methods: 
In this observational study, patients with moderate to severe OSA underwent 24h central and 
peripheral BP testing before and after at least 4 weeks of CPAP therapy. Concurrent actigraphy was 
performed to confirm sleep and wake times.  
Results: 
36 patients were screened, 31 had successful testing (mean (SD) age 45 ± 10 years, AHI 58 ± 27 
events/hr, Office BP 136/89 ± 10.7/9.5mmHg, 32% on anti-hypertensives, 77% dippers), 21 completed 
testing post CPAP.  Central systolic and diastolic BP followed the same nocturnal dipping profile as 
peripheral BP, however the peripheral pulse pressure (PP) narrowed in sleep (-3.2mmHg, p<0.001), 
whereas the central PP remained unchanged (0.124mmHg, NS), causing a significant reduction in PPA 
overnight (-10.7%, p<0.001). The magnitude of dip in central systolic pressure was less than peripheral 
systolic pressure (by 2.3mmHg, p<0.001). After treatment with CPAP, the PPA reduction overnight was 
attenuated (by -3.3%, p=0.004). 
Conclusions: 
In moderate to severe OSA, central BP and PPA reduce overnight during sleep. Further randomised 
controlled studies are needed to quantify the differential effects of CPAP and anti-hypertensives on 
central versus peripheral BP.  
Keywords: blood pressure, hypertension, sleep-disordered breathing 
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3.1.2 Introduction 
 
Obstructive sleep apnoea (OSA) is strongly associated with hypertension1 2 and widely accepted as a 
risk factor for secondary hypertension.3 4 Management of hypertension is more challenging in patients 
with OSA as evidenced by higher rates of refractory hypertension, greater nocturnal non-dipping,5-7 
and sub-optimal responses to anti-hypertensives.8 9 Furthermore, treatment of OSA with continuous 
positive airway pressure (CPAP) confers surprisingly modest benefits in terms of reducing blood 
pressure.10 Hence, the mechanisms underpinning hypertension in OSA and how best to manage it in 
this vulnerable group is still poorly understood.  
For decades, office peripheral (brachial) blood pressure (BP) as measured in a clinic setting has been 
used to determine future cardiovascular risk. However, 24h ambulatory blood pressure monitoring 
(ABPM) has established itself as a superior predictor of cardiovascular mortality and morbidity.11 12 In 
particular, the ability to determine nocturnal blood pressure dipping status has greatly improved risk 
stratification.13 Despite these advances, a major limitation of peripheral systolic BP is that it does not 
accurately represent central (aortic) systolic BP. This is because systemic arterial stiffness and its 
impact on wave reflection can vary both within individuals across time14 and between individuals. This 
variation in arterial stiffness and in heart rate will directly alter the magnitude of the reflected 
component of the pulse pressure wave (augmentation pressure) which will in turn alter central aortic 
systolic pressure. Importantly, several studies have shown that static measurements of central BP 
have been associated with target-organ damage15 16 and cardiovascular risk, independent of 
peripheral BP.17 18 
In this context, a key recent technological advancement has been the development of ambulatory BP 
devices that are able to capture not only inter-individual differences but also day-night changes in 
both peripheral and central (aortic) blood pressure.19 By quantifying sleep aortic BP in particular this 
technology has the potential to greatly improve risk stratification. Furthermore, studies have shown 
that anti-hypertensive medications have differential effects on central aortic as opposed to peripheral 
BP which has significant therapeutic implications.20 Additionally, the difference between central and 
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peripheral blood pressure, known as pulse pressure amplification (PPA), is emerging as an important 
novel predictor of future cardiovascular events. 21-23 This new ambulatory technology therefore allows 
the examination of wake-sleep changes in PPA thereby providing further novel insights into arterial 
haemodynamics. 
To date there have not been any published studies that have examined 24 hour central blood pressure 
and PPA in patients with OSA. Additionally, there have been no studies of the diurnal properties of 
central BP in this population before and after treatment with CPAP.  In this study, we sought to 
describe for the first time the diurnal nature of peripheral and central blood pressure and PPA over a 
24 hour period in patients with moderate to severe OSA. We also quantified in a smaller group, the 
relative wake-sleep changes in peripheral and central BP after treatment with CPAP therapy.  
3.1.3 Methods 
 
Study design 
This was an observational study examining the diurnal profile of peripheral and central blood pressure 
and pulse pressure amplification in OSA patients before and after CPAP therapy. The study protocol 
was approved by the NSW Sydney Local Health District Ethics committee (X15-0360 & 
HREC/15/RPAH/490). All patients signed a written informed consent. 
Participants  
Participants were recruited from a Sleep clinic (Woolcock Institute of Medical Research, Sydney, 
Australia) between September 2016 and October 2017. Male and female participants were eligible if 
they were aged 18 to 65yo, had moderate to severe untreated hypoxemic OSA (Apnoea-Hypopnea 
Index and Oxygen Desaturation Index-3% ≥15/hr), and on fewer than three anti-hypertensive 
medications. Patient exclusion criteria were: severe hypertension (Office Systolic blood pressure≥180 
mmHg and/or Diastolic blood pressure≥110 mmHg), severe OSA (minimum oxygen saturation ≤65% 
or Respiratory Disturbance Index>80/hr) with excessive sleepiness at high risk of driving-related 
accidents, chronic kidney disease (eGFR<60) and uncontrolled medical problems.  
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All patients underwent gold standard overnight in-laboratory polysomnography to confirm OSA status 
and severity. Studies were scored according to the American Academy of Sleep Medicine criteria.24 
Once eligible, patients were fitted with the ambulatory blood pressure monitor and cuff (Oscar2 with 
SphygmoCor Inside, SunTech Medical, Model 250, NC, USA). The appropriate sized cuff was 
determined by measuring the patient’s upper arm circumference. The device is a non-invasive 
oscillometric ambulatory blood pressure monitor and brachial cuff that is worn by the patient in the 
community. The machine was set to take readings every 30 minutes over a 24hour period. At these 
set intervals, the cuff inflates to obtain systolic and diastolic pressures based on pressure waves in the 
artery when occluded by pressure in the cuff (oscillometric method). The machine then deflates to 
10mmHg below diastolic pressure and captures volumetric waveforms. It then derives central arterial 
indices from the captured waveforms using a validated transfer function algorithm. As a peripheral BP 
device, the Oscar2 has met all requirements according to the International Protocol for the validation 
of blood pressure machines and the British Hypertension Society. 25 26  The cuff-based measurement 
of brachial pressure waves in the Oscar2 and the transfer function for estimating central BP and 
augmentation index is identical to the SphygmoCor XCEL. This cuff-based technology has been 
compared against the gold standard non-invasive radial tonometry technology originally developed 
for SphygmoCor pulse wave analysis machines27 28 which were validated against invasive measures of 
central BP.29 More recently, the SphygmoCor XCEL estimates of central BP were found to highly 
correlate with invasively measured brachial and central BP.30  The studies have shown that estimates 
of central BP and wave reflection are acceptably accurate and exceed criteria for repeatability and 
reliability. 19 31 32 
Concurrently, patients wore an actiwatch and completed sleep diaries to document their sleep and 
wake times.  Actigraphy data was analysed manually using Actiware (Phillips Actiware v.6, Respironics 
Inc, Murrysville PA, USA). The actiware options and settings were as follows: 1. wake threshold 
selection was set at medium, 2. immobile minutes for sleep onset and sleep end were set at 5 minutes. 
However, one patient demonstrated very frequent movements during sleep and for this study the 
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immobile minutes setting was reduced to zero minutes in order for the software to recognise the 
period as sleep. Based on the results of the analysed actogram, the investigator then assigned a status 
of either wake or sleep to each blood pressure recording taken over the 24 hour period.  
Patients were on CPAP for a minimum of 4 weeks before repeat 24h ABPM testing was performed. 
The settings for CPAP pressure were determined in either one of two ways depending on clinician 
preference. Either during a single overnight in-laboratory pressure titration sleep study where the 
pressure was manually titrated until obstructive events were abolished, or by placing the patient on 
auto-CPAP for a period of 2 weeks and then setting a fixed CPAP pressure based upon the 95th centile 
pressure applied during the preceding 2 weeks. Patients were reviewed by the CPAP therapist two 
weeks after commencement of CPAP for optimisation of therapy and at the end of the trial. Patients 
were reviewed more frequently if the CPAP therapist felt it was clinically indicated to help optimisation 
and acclimatisation to therapy. 
Prior to statistical analysis, all 24h-ABPM data that was deemed artefactual was identified and 
removed based on Staessen’s criteria which included the following readings: systolic blood pressure 
>240 or <50mmHg, diastolic blood pressure (DBP)> 140 or <40mmHg, heart rate (HR)>150 or 
<40beats/min, and pulse pressure >10% of SBP.33 As for the central indices, if the augmentation index 
(AIx) was ≤-80, or >60, this was deemed artefactual and excluded along with the corresponding 
augmentation pressure (AP) and augmentation index corrected for heart rate (AIX@75) taken during 
that measurement. Central HR was used rather than peripheral HR as the method of collection is more 
accurate. The machine measures central HR from the length of the cardiac pulse, whereas peripheral 
HR is calculated by counting pulses during the oscillometric BP measurement. If peripheral HR and 
central HR differed by >10 beats per minute (bpm) then the central measurements were excluded as 
it indicated a poor quality waveform and only peripheral SBP and peripheral DBP were retained for 
those readings. 
After artefactual readings were excluded, studies were reviewed and deemed unsuccessful if they 
contained less than 20 valid daytime readings or less than 7 valid night time readings as per European 
81 
 
Society of Hypertension guidelines (see flowchart for numbers of excluded studies based on these 
criteria).34  
Statistical Analysis 
Linear mixed models analyses were used to examine changes in peripheral blood pressure, central 
blood pressure and indices of wave reflection (AIx, AP) and PPA both before and after CPAP in sleep 
and wake. A paired t-test was used to compare the wake-sleep change in peripheral SBP and central 
SBP using mean wake to sleep differences for each patient. All statistical analyses were performed 
using IBM SPSS version 22.0 for Windows system (SPSS Inc., Chicago, IL). PPA was calculated as the % 
increase from central to peripheral pulse pressure as follows: ((Peripheral SBP–Peripheral DBP)–
(Central SBP–Central DBP))/(Central SBP–Central DBP)) x 100. Non-dipping status was determined by 
((Sleep SBP – Wake SBP)/Wake SBP) x 100 ≤ 10%.  
3.1.4 Results 
 
36 patients were screened and were potentially eligible, 31 patients had successful baseline 24h ABPM 
testing and 21 of these patients had successful post CPAP testing. The flow chart in Figure 1 details 
exclusions and reasons.  
Patient baseline characteristics are shown in Table 1. The baseline characteristics in the patients that 
went on to CPAP were similar (data not shown). The mean age was 45 ± 10 years and 77% were male. 
Overall the OSA was severe with mean AHI 58 ± 27 events/hr and patients were obese (mean BMI 32.3 
± 5.8 kg/m2).  Hypertension was previously diagnosed in 32% of the patients and all were on 
antihypertensive therapy, however the mean office BP was within normal limits (SBP 136 ± 10.7mmHg 
DBP 89 ± 9.5 mmHg). Patients had an average nightly CPAP compliance of 5.12 ± 1.0 hrs with a residual 
AHI of 4.2 ± 3.3 events per hour. 
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Changes in Peripheral and Central Blood Pressure and Pulse Pressure Amplification Indices between 
wake and sleep 
Baseline peripheral and central blood pressure indices from wake to sleep are shown in table 2. Both 
peripheral and central SBP and DBP and HR reduced significantly from wake to sleep demonstrating a 
diurnal dipping pattern (Figure 2). Central SBP and DBP both reduced by equal amounts of 17mmHg, 
however peripheral SBP dropped by 19mmHg, whereas peripheral DBP dropped by 16mmHg, 
effectively narrowing the peripheral pulse pressure in sleep. The reduction in central SBP was less than 
that of peripheral SBP (difference 2.3 mmHg, p<0.001). 
Effects of CPAP on Peripheral and Central BP during wake and sleep 
All central and peripheral BP indices before and after CPAP are presented in Table 3. The most notable 
changes occurred in wake measurements. Wake peripheral and central DBP and HR were reduced 
after treatment with CPAP whereas wake indices of wave reflection (C_AP, C_AIx, C_AIx 75) increased 
after treatment. In contrast, sleep indices remained largely unchanged apart from a small drop in HR 
and a small increase in C_AP. These CPAP associated changes during wakefulness subsequently altered 
the sleep related changes seen prior to CPAP. In particular, the wake related reduction in C_DBP after 
CPAP significantly reduced the magnitude of the subsequent sleep related dip that was present before 
CPAP by 2.4mmHg (p=0.016). Similarly, the wake related increase in arterial stiffness with CPAP 
attenuated the magnitude of the sleep related rise in C_AP by 2.2mmHg (p<0.001) and resulted in an 
absolute reduction in sleep AIx_75 by 4.6% (p<0.001). 
Finally, before CPAP there was a large (~12%) reduction in PPA from wake to sleep due to differential 
reductions in peripheral and central pulse pressure. After CPAP this nocturnal fall in PPA (~9%) was 
attenuated by 3.3% (p<0.004).   
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Figure 1. Study flowchart. ABPM, ambulatory blood pressure monitoring; CPAP, Continuous positive 
airway pressure. Studies were deemed unsuccessful based on European Society of Hypertension 
guidelines. 
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Table 1. Baseline characteristics of all patients* 
Characteristic Measure 
Demographics(±SD)   
Age,yr 45 ± 10 
Male/female,n 24/7 
BMI, kg/m2 32.3 ± 5.8  
Waist circumference, cm 107.8 ± 10.6 
Neck circumference, cm 41.9 ± 3.7 
ESS 10 ± 5.4 
Office SBP, mmHg 136 ± 10.7 
Office DBP, mmHg 89 ± 9.5 
Ambulatory Blood Pressure    
Non-dippers, n (%)^  7 (23) 
Dippers, n (%)^ 24 (77) 
Medical history, n (%)  
Hypertension 10 (32) 
Type 2 diabetes 0 (0) 
Hypercholesterolemia 4 (13) 
Stroke 0 (0) 
Heart failure/Ischaemic heart disease 0 (0) 
Current Smoker 2 (6) 
Ex-smoker 12 (39)  
Anti-hypertensives at baseline, n (%)  
Prescribed 10 (32)  
1 antiHTN 5 (16) 
2 antiHTN 4 (13) 
3 antiHTN  1 (3) 
PSG  values (±SD)  
AHI, events/h 58 ± 27 
ODI, events/h 49 ± 27 
Min Sa02, % 75 ± 11 
* Patients included those with successful baseline 24hABPM (n=31) 
Plus-minus values are means ± standard deviation. BMI – Body-mass index (weight in kilograms 
divided by the square of the height in metres), ESS – Epworth Sleepiness Scale, PSG – Polysomnogram, 
AHI – Apnea-hypopnea index, ODI – Oxygen desaturation index, SaO2 denotes oxygen saturation level 
as measured by pulse oximetry.  
δPPA was calculated as ((P_SBP – P_DBP) – (C_SBP – C_DBP))/(C_SBP – C_DBP)) x 100 
^Non-dipping status was determined by ((Sleep SBP – Wake)/Wake SBP) x 100  ≤ 10% 
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Table 2. Peripheral and central ambulatory blood pressure monitoring results in untreated patients 
n=31* 
 
 
 
 
 
 
*Data were analysed using linear mixed models; Values are mean ± standard error, (95% CI);  
P_SBP, Peripheral systolic blood pressure; P_DBP, Peripheral diastolic blood pressure; C_SBP, central 
systolic blood pressure; C_DBP, central diastolic blood pressure; C_HR, central heart rate; C_AP, 
central augmentation pressure; C_AIx, central augmentation index; C_AIx 75, central augmentation 
index corrected for heart rate; P_PP, peripheral pulse pressure, C_PP, central pulse pressure; PPA, 
pulse pressure amplification  
^PPA calculated as ((P_SBP – P_DBP) – (C_SBP – C_DBP))/(C_SBP – C_DBP))*100 
Variable Wake 
 
Sleep 
 
Difference 
(sleep 
minus 
wake) 
P value 
P_SBP, mmHg 134.8 ± 2.0 
(130.8 to 138.8) 
115.6 ± 2.0 
(111.5 to 119.7) 
-19.2 <0.001 
P_DBP, mmHg 83.8 ± 1.4 
(80.9 to 86.6) 
67.7 ± 1.5 
(64.8 to 70.7) 
-16.0 <0.001 
C_SBP, mmHg 123.9 ± 1.8 
(120.3 to 127.5) 
106.9 ± 1.8 
(103.2 to 110.5) 
-17.1 <0.001 
C_DBP, mmHg 85.3 ± 1.5 
(82.3 to 88.4) 
68.2 ± 1.5 
(65.1 to 71.3) 
-17.2 <0.001 
C_HR, bpm 80.7 ± 1.6 
(77.4 to 84.0) 
66.9 ± 1.6 
(63.6 to 70.2) 
-13.8 <0.001 
C_AP, mmHg 12.5 ± 0.7 
(11.1 to 14.0) 
14.7 ± 0.7 
(13.1 to 16.2) 
2.14 <0.001 
C_AIx, % 31.0 ± 1.3 
(28.3 to 33.7) 
37.3 ± 1.4 
(34.5 to 40.1) 
6.3 <0.001 
C_AIx 75, % 33.7 ± 1.4 
(30.8 to 36.6) 
33.4 ± 1.5 
(30.4 to 36.4) 
-0.319 0.661 
P_PP, mmHg 51.0 ± 1.3 
(48.4 to 53.7) 
47.8 ± 1.4 
(45.1 to 50.6) 
-3.2 <0.001 
C_PP, mmHg 38.7 ± 1.1 
(36.5 to 40.9) 
38.6 ± 1.1 
(36.4 to 40.8) 
0.124 0.795 
PPA, %^ 33.3 ± 1.1 
(31.0 to 35.6) 
22.6 ± 1.2 
(20.1 to 25.0) 
-10.7 <0.001 
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Figure 2. Ambulatory peripheral and central blood pressure profile over 24 hours in untreated 
patients with OSA. The top panel depicts the percentage of blood pressure readings scored as wake 
in all patients at any given hour across the 24 hour period based on actigraphy analysis. The bottom 
panel depicts the overall mean blood pressure values every hour across the 24 hours. The shaded area 
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schematically represents augmentation pressure and P1 represents unaugmented central systolic 
pressure. P_SBP, Peripheral systolic blood pressure; P_DBP, Peripheral diastolic blood pressure; 
C_SBP, central systolic blood pressure; C_DBP, central diastolic blood pressure.  
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Figure 3. 24-hour association between PPA and HR in untreated OSA (a) Pulse pressure 
amplification (b) central HR (c) correlation between change in PPA from wake to sleep versus 
change in HR from wake to sleep  
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Table 3. Peripheral and central ambulatory blood pressure monitoring results in patients before 
after treatment with CPAP therapy, n=21* 
 
 
*Data were analysed using linear mixed models; Values are mean ± standard error (95% CI); P_SBP, 
Peripheral systolic blood pressure; P_DBP, Peripheral diastolic blood pressure; C_SBP, central 
systolic blood pressure; C_DBP, central diastolic blood pressure; C_HR, central heart rate; C_AP, 
central augmentation pressure; C_AIx, central augmentation index; C_AIx 75, central augmentation 
index corrected for heart rate; P_PP, peripheral pulse pressure, C_PP, central pulse pressure; PPA, 
pulse pressure amplification; ^PPA calculated as ((P_SBP – P_DBP) – (C_SBP – C_DBP))/(C_SBP – 
C_DBP))*100 
 
Variable Wake Sleep 
 Before CPAP 
 
After CPAP 
 
Change P value Before CPAP 
 
After CPAP 
 
Change P 
value 
P_SBP, 
mmHg 
133.0 ± 1.6 
(129.6 to 136.4) 
133.4 ± 1.6 
(130.0 to 136.8) 
0.414 0.557 112.2 ± 2.0 
(108.0 to 
116.4) 
112.2 ± 2.0 
(108.1 to 
116.4) 
0.036 0.968 
P_DBP, 
mmHg 
84.3 ± 1.3 
(81.5 to 87.1) 
82.0 ± 1.3 
(79.2 to 84.4) 
-2.287 <0.001 66.7 ± 1.4 
(63.7 to 69.7) 
66.2 ± 1.4 
(63.2 to 69.2) 
-0.447 0.518 
C_SBP, 
mmHg 
122.5 ± 1.6 
(119.3 to 125.7) 
123.0± 1.6 
(119.8 to 126.2) 
0.492 0.458 104.2 ± 1.8 
(100.4 to 
108.0) 
105.6 ± 1.8 
(101.8 to 
109.4) 
1.428 0.113 
C_DBP, 
mmHg 
85.8 ± 1.4 
(83.0 to 88.6) 
83.1 ± 1.4 
(80.3 to 85.9) 
-2.640 <0.001 67.4 ± 1.5 
(64.3 to 70.4) 
67.2 ± 1.5 
(64.1 to 70.3) 
-0.188 0.799 
C_HR, 
bpm 
80.2 ± 2.0 
(76.0 to 84.3) 
77.2 ± 1.9 
(73.0 to 81.4) 
-2.931 <0.001 66.5 ± 1.5 
(63.3 to 69.7) 
63.4 ± 1.5 
(60.2 to 66.6) 
-3.108 <0.001 
C_AP, 
mmHg 
11.2 ± 1.0 
(9.2 to 13.2) 
14.4 ± 1.0 
(12.4 to 16.4) 
3.146 <0.001 13.8 ± 0.7 
(12.3 to 15.2) 
14.8 ± 0.7 
(13.3 to 16.2) 
1.028 0.014 
C_AIx, 
% 
29.1 ± 1.7 
(25.5 to 32.6) 
34.6 ± 1.7 
(31.0 to 38.2) 
5.554 <0.001 36.7 ± 1.4 
(33.8 to 39.6) 
37.9 ± 1.4 
(35.0 to 40.8) 
1.16 0.122 
C_AIx 
75, % 
31.5 ± 1.6 
(28.1 to 34.9) 
35.7 ± 1.6 
(32.4 to 39.1) 
4.283 <0.001 32.7 ± 1.8 
(28.9 to 36.5) 
32.4 ± 1.8 
(28.7 to 36.2) 
-0.283 0.713 
P_PP, 
mmHg 
48.7 ± 1.2 
(46.3 to 51.1) 
51.4 ± 1.2 
(49.0 to 53.8) 
2.701 <0.001 45.5 ± 1.1 
(43.2 to 47.9) 
46.0 ± 1.2 
(43.6 to 48.4) 
0.469 0.488 
C_PP, 
mmHg 
36.7 ± 1.2 
(34.3 to 39.1) 
39.8 ± 1.2 
(37.4 to 42.3) 
3.126 <0.001 36.8 ± 0.9 
(34.9 to 38.7) 
38.5 ± 0.9 
(36.6 to 40.4) 
1.695 0.003 
PPA, %^ 34.3 ± 1.6 
(31.0 to 37.5) 
28.9 ± 1.6 
(25.7 to 32.2) 
-5.338 <0.001 22.4 ± 0.9 
(20.5 to 24.3) 
20.2 ± 0.9 
(18.3 to 22.1) 
-2.185 <0.001 
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3.1.5 Discussion 
This is the first study to demonstrate the diurnal pattern of central blood pressure (BP) and pulse 
pressure amplification (PPA) in patients with moderate to severe OSA. We also describe for the first 
time in a small number of patients, the changes in 24hour central BP and PPA after CPAP treatment. 
We found that similar to peripheral BP, central BP dips during sleep. However, systolic and diastolic 
BP reduced by different amounts in sleep peripherally and centrally, causing a reduction in peripheral 
pulse pressure whilst there was no change in the central pulse pressure. This led to a reduction in PPA 
overnight. This attenuation in PPA was consistent with our findings of an increase in wave reflection 
during sleep. These results highlight the fact that peripheral BP and central BP and its components 
behave differently. With CPAP, this attenuation was unexpectedly diluted– not because of a 
hypothesised decrease in wave reflection during sleep, but instead because of a paradoxical increase 
during wakefulness.  
Our 24hour CBP and PPA findings in untreated OSA patients are similar to other very recent studies in 
hypertensive and normotensive populations without OSA.19 35-37  However to date, only one of these 
studies explored central BP data with the same Oscar 2 device used in our study.19 This study in 40 
healthy participants demonstrated good-to-excellent inter-day reliability and validity of the Oscar 2 
device by comparing static measures with ambulatory values and by repeating ambulatory measures 
in individuals at different time points. Similar to our study in OSA, they found in healthy participants 
that the magnitude of drop during the night in central SBP was attenuated as compared to peripheral 
SBP. The absolute reductions in peripheral and central SBP were comparable to our study (20mmHg 
and 15mmHg respectively, compared to 19mmHg and 17mmHg in our study).  
For any given peripheral SBP, the central SBP will be lower and the magnitude of the difference is 
measured as pulse pressure amplification. Hence pulse pressure amplification refers to the 
phenomenon whereby pulse pressure (or the difference between SBP and DBP) increases when 
moving distally from the heart to the peripheral arterial tree. This amplification in healthy people 
91 
 
represents normal physiology, however factors such as aging, and CV risk factors such as hypertension, 
diabetes mellitus and established CV disease are associated with reduced PPA21 – which is thought to 
be  chiefly due to a relative increase in aortic SBP as a consequence of increased wave reflection.38 39 
The development of ambulatory devices that measure central and peripheral BP has revealed that 
PPA, like peripheral SBP, also dips nocturnally.35-37 40 To the best of our knowledge, we are the first to 
report on 24 hour PPA in patients with OSA, finding that PPA reduced by 10% from wake to sleep. 
Consistent with previous studies in non-OSA groups, we have shown that PPA dipping occurs because 
of a greater sleep reduction in peripheral pulse pressure as compared to central pulse pressure.35-37 40  
With regards to wave reflection (C_AP, C_AIx), several 24 hour studies in hypertensives and 
normotensives have found that this increases at night 37 40 41 and this likely explains the reduction in 
PPA during sleep. In our patients with OSA, we found a sleep-related rise of 2mmHg in augmentation 
pressure and 6% in augmentation index but this effect was negated when corrected for heart rate 
(C_AIx 75).  Only one other study has performed ambulatory measures of AIx in OSA (albeit with a 
different device and the authors did not report on corresponding central blood pressures) and found 
no change from day to night.42 Interestingly, this study also found that control subjects without OSA 
had a significant drop in AIx from day to night. This contrasts with another much larger study of 500 
non-OSA patients (using the same device) which showed a rise in AIx.40 It is unclear whether the device 
used had undergone any formal validation to assess the accuracy of the AIx derivation. Certainly, the 
only directly comparable study to ours, using the validated Oscar 2 (which also measures central BP) 
found a 4mmHg rise in augmentation pressure, 9% rise in AIx and 3% rise in AIx corrected for HR from 
daytime to nighttime.19 These changes in young healthy controls are approximately two-fold greater 
than the changes we observed in our OSA patients and leads us to speculate that the sleep-related 
increase in systemic arterial stiffness (as measured by augmentation pressure and augmentation 
index), is likely to represent normal physiology.  
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The mechanisms underpinning the drop in PPA and increase in wave reflection which have been 
shown across studies are not fully understood. It could be argued that these overnight changes could 
be attributed to changes in posture given the findings of a well-designed study which performed static 
measurements in awake individuals in the sitting and supine position43 The study found that in the 
recumbent (supine) position, PPA was reduced, whilst measures of wave reflection (augmentation 
pressure and AIx) all increased.43 However the absolute sitting-supine change in PPA was less than 4% 
as compared to nearly ~11% in our OSA patients and ~9% in the aforementioned healthy control study. 
19 Hence although recumbent posture might account for some of the overnight change, there are likely 
to be other mechanisms involved. In this context, the bulk of the increase in augmentation pressure 
in our study appeared to occur from midnight when most participants were (according to actigraphy) 
asleep (Figure 2 top panel and shaded area – bottom panel), suggesting that a change associated with 
sleep itself is a likely contributing factor. These changes might include a reduction in sympathetic tone 
which could impact on both vascular tone and heart rate which both impact on the magnitude of wave 
reflection. 
In the context of changes in heart rate with sleep, these likely contribute to both the wake-sleep PPA 
and AIx changes. It has already been established in studies using static measures that PPA and AIx are 
directly and inversely related to HR, respectively.38 39 In support of this, our analysis found a strong 
relationship between the wake to sleep change in HR and PPA (r=0.648, p<0.001, Figure 3) in keeping 
with other 24 hour study findings.36 40 This reduction in HR during sleep increases the duration of 
ventricular ejection, thereby exposing the left ventricle to a greater proportion of the reflected wave 
from the lower body. This acts to augment the forward pressure wave in systole thereby increasing 
augmentation pressure and central systolic blood pressure.38 39 This potentially accounts for the 
attenuated nocturnal dip in central SBP as compared to peripheral SBP. In Figure 2, we demonstrate 
schematically this increase in augmentation pressure (shaded area) in parallel with the dampening of 
the central SBP dip during the night.  
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Multiple meta-analyses of RCTs have demonstrated that CPAP results in a modest reduction in SBP of 
approximately 2-3mmHg in patients with OSA and HTN.44 45 46-48 Only one study has looked at the effect 
of CPAP on 24h-ABPM in normotensive OSA patients and found that whilst the SBP was unchanged, 
24hour DBP and daytime DBP reduced significantly by 1.38mmHg and 1.39mmHg respectively.49 
Similarly, in our mostly normotensive patients, treatment with CPAP resulted in a reduction in wake 
peripheral and central DBP as well as wake and sleep HR. We had postulated that following elimination 
of OSA with CPAP, there would be also be a reduction in wave reflection across both the wake and 
sleep periods. Instead there was an increase during the wake period after CPAP. Whilst the cause for 
the wake-related increase is unclear, it did not carry through to the subsequent sleep period. Although 
highly speculative, this lack of absolute change in the magnitude of wave reflection during sleep may 
represent the sum effect of a relative nocturnal reduction (due to elimination of OSA) and a relative 
nocturnal increase (due to restoration of a ‘normal’ physiological rise) as seen in healthy people.19  
The increase in wave reflection (AP, AIx and CAIx75) during wakefulness after CPAP is contrary to the 
findings from other studies using static office-based measurements which have consistently shown a 
reduction.50 51 Similarly, an attenuated PPA dip with CPAP is difficult to explain seeing as the expected 
effects of treatment overnight such as a reduction in sympathetic activity, and reduction in left 
ventricular afterload, should all theoretically cause a further reduction in sleep PPA. Interestingly, a 
large cross-sectional 24 hour study of patients with suspected or established hypertension 
paradoxically found one of the factors associated with less PPA dipping at night was the use of 
antihypertensives.40 Also of interest is that beta blockers, unlike other anti-hypertensives, have been 
shown to decrease PPA, by having a much more marked effect on lowering peripheral BP as compared 
to central BP.52 Clearly the impact of blood pressure lowering treatments on the haemodynamic 
changes between wake and sleep are complex and not yet fully understood. Ultimately, although the 
effect of CPAP involved only a relatively small sample of patients, we did find in secondary analyses 
(results not shown) that the increase in wake AP after CPAP was a consistent finding in 19 of the 21 
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patients studied. Nevertheless these effects need to be replicated with a larger study and appropriate 
control group.  
Overall, whilst this study is novel in exploring central hemodynamic changes across the sleep-wake 
cycle in OSA, it is limited by its observational design and small sample size. It is further limited by an 
even smaller sample of patients completing the CPAP follow up. Secondly, a non-OSA comparator 
group would have strengthened the study, as well as a sham CPAP arm to confirm that the changes 
were related to CPAP use.  Given the lack of a control group, we compared our baseline values to a 
study with healthy participants (albeit of a younger demographic with a greater proportion of females) 
that used the same device. Finally, despite the severity of the underlying OSA, the group were largely 
normotensive and it remains to be determined whether similar wake-sleep changes in central BP and 
PP amplification would occur in a hypertensive OSA group and whether CPAP treatment would 
differentially alter these measures. The strengths of this study were that we utilised gold standard in- 
lab polysomnography for accurate identification of our patients, and more importantly, we utilised 
individualised wake and sleep times for each patient by using actigraphy as well as sleep diaries. This 
means that measures of sleep-wake changes are technically more accurate and this has not been 
replicated in any of the other 24 hour central BP studies. Lastly, we used a blood pressure device that 
was validated not only for central BP readings but also for AIx.   
New ambulatory technology has allowed us to describe for the first time the diurnal variation of 
central blood pressure and pulse pressure amplification in OSA, a population at risk of poor 
cardiovascular outcomes. There is emerging data to suggest that these hemodynamic findings may be 
better predictors of target organ damage and future cardiovascular risk than peripheral brachial 
measurements. Central blood pressure is importantly, a more accurate representation of end-organ 
BP exposure including the heart and kidneys. Furthermore, central BP changes differently to 
peripheral blood pressure during sleep and to different anti-hypertensives.  This study paves the way 
for future research in the hypertensive OSA population, specifically, examining the effects of CPAP on 
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central blood pressure and differential therapeutic and chronotherapeutic effects of various classes 
of anti-hypertensives.  
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4 CHAPTER FOUR 
 
4.1 SUMMARY 
 
The purpose of this thesis was firstly to develop a strategy to improve the treatment of hypertension 
in patients with OSA, by maximising the application of pharmacotherapy, and secondly to discover a 
biomarker for future prognostication and therapeutic intervention. These aims were motivated by the 
underlying premise that patients with OSA display a different underlying pathophysiology as 
compared with essential hypertensives, and hence deserve a dedicated approach to treatment of their 
hypertension. In both our studies, the central theme related to 24 hour blood pressure monitoring, 
specifically with the aim of examining and targeting nocturnal blood pressure – the strongest predictor 
of cardiovascular mortality.  
In the first study we applied the principle of chronotherapy to the treatment of hypertension in OSA. 
We performed a robust randomised double blinded placebo-controlled cross-over trial in 79 patients 
with moderate to severe OSA with grade 1 or 2 hypertension. In contrast to a large number of previous 
chronotherapy trials in patients with essential hypertension,1 we did not find nocturnal administration 
of a once daily ACE-inhibitor at maximal dose to be superior in reducing nocturnal BP as compared to 
morning administration. Instead, we found that morning administration resulted in better daytime BP 
values and equivalent nocturnal values. We also sought to determine whether the addition of CPAP 
would confer any additional BP lowering benefit which involved an open-label CPAP arm at the 
conclusion of the study. We found that the addition of CPAP further lowered sleep SBP but that 
applying it in conjunction with evening dosing did not confer any additional benefit as compared with 
morning dosing. 
These results were unexpected and difficult to explain but raised two important points. Firstly, that 
although there is a large volume of chronotherapy studies in various hypertensive populations 
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demonstrating positive findings in lowering nocturnal BP, all of these had methodological flaws, and 
none were double blinded placebo controlled RCTs like our study. It has been well established that 
placebo medications can lower BP significantly (up to 6mmHg in non-resistant hypertensives).2 3 This 
magnitude of reduction could easily adversely affect study results if patients are expecting to receive 
a benefit from nocturnal dosing. Secondly, if we assume that chronotherapy is indeed effective, 
(despite methodological flaws) then our study highlights the underlying pathophysiological 
differences that exist in patients with OSA and hypertension. We suspect that the excessive nocturnal 
sympathetic activation seen in OSA may be counteracting the BP-lowering effect of nocturnal 
perindopril. Furthermore, the sympathetic-parasympathetic imbalance could potentially affect the 
usual circadian pharmacokinetics and pharmacodynamics of perindopril, perhaps making it less 
effective. These theories are as yet unproven. 
In our second study, we sought to discover a new biomarker to aid our understanding of the underlying 
arterial haemodynamics in OSA.  In 2005, using single time-point measures in patients with OSA, 
Phillips et al discovered that central BP and AIx reduced overnight whilst peripheral BP remained 
unchanged.4 This 2005 study was the first to suggest a potential dynamic diurnal variation of arterial 
stiffness in OSA, and to highlight the potentially differing behaviours of central and peripheral BP. This 
concept was not explored further until recently, thanks to the advent of new technology allowing the 
24 hour ambulatory measurement of central BP and of markers of wave reflection.  
In our observational study, we examined the diurnal variation of central BP and peripheral BP in 
patients with moderate to severe OSA. In an exploratory subgroup, we compared the results after at 
least 4 weeks of CPAP therapy.   We found, in our 31 patients, that central BP followed the same 
dipping profile as peripheral BP, but that the peripheral pulse pressure narrowed in sleep, whilst the 
central pulse pressure remained unchanged, leading to a reduction in pulse pressure amplification 
(PPA) overnight. Central systolic pressure dipped less than peripheral systolic pressure overnight. As 
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a surrogate measure of arterial stiffness, AIx increased during the night, but not when corrected for 
heart rate. 
Our 24 hour central BP, peripheral BP and PPA results were similar to other recent studies in 
hypertensive and normotensive populations without OSA.5-8 However, in contrast to previous studies, 
5 8-10 we did not find a sleep-related increase in AIx (when corrected for HR). Based on the findings of 
these studies, we postulate that a sleep-related increase in AIx likely represents normal physiology 
and that this effect is dampened or absent in patients with OSA.  
In 21 patients after CPAP, as expected, the wake peripheral and central DBP reduced, but there was 
an unexpected attenuation of the overnight dip in PPA. Also unexpectedly, there was an increase in 
AIx during wakefulness, contrary to studies that have performed static office-based measurements 
which have consistently shown reductions. In our study’s discussion, we propose several theories for 
these results. 
One major limitation of our study was that we did not have a non-OSA control group to directly 
compare our own baseline values, secondly, our sample size was small, particularly in the post CPAP 
arm. Our study paves the way for larger studies with appropriate control groups, and eventually for 
trials using therapeutic interventions such as with weight loss, pharmacotherapy and device based 
interventions.  
A particular strength of both of our studies, was the novel complementary use of actigraphy in 
conjunction with sleep diaries, to more accurately identify individualised sleep-wake times. To our 
knowledge, this technique has not been applied to any of the 24 hour BP studies thus far. In most 
studies, either blanket sleep-wake times were applied to all patient data, or less commonly, sleep-
wake times were obtained from subjective sleep-diaries alone. 
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4.2 CONCLUSION  
 
The editorial written by Tamisier and colleagues in response to our first study was entitled rather 
rhetorically and very aptly “Do patients with obstructive sleep apnoea deserve new dedicated anti-
hypertensive strategies?”  Throughout this thesis we have sought to deliver on a dedicated approach 
and strategy, given the unique features of the OSA population.  
Although we did not find a chronotherapeutic benefit with nocturnal perindopril, we highlighted the 
complexities and underlying differences between the OSA hypertensive and their need for a distinct 
therapeutic approach. In our second study, we demonstrated for the first time, a potential tool or 
biomarker to move forward in the ongoing quest to solve the mysteries surrounding the difficult to 
treat hypertension in this vulnerable group. By using a novel piece of technology that measures 24 
hour central blood pressure, we demonstrated that central and peripheral BP, and surrogate markers 
of wave reflection behave differently over a 24 hour period. This study paves the way for 
interventional studies and will hopefully shed more light on the pathophysiological differences in the 
OSA population.  
4.3 FUTURE DIRECTIONS 
 
In future, what are needed are interventional studies, be they weight loss, pharmacological or device 
based interventions, that specifically examine the effects on 24 hour central and peripheral BP as 
compared with either non-OSA or sham device comparator groups.  These should be designed as 
larger studies with longer follow up periods. Given their particular effectiveness in comparison to 
other interventions, antihypertensive strategies in OSA deserve further examination, and 
chronotherapy with other anti-hypertensive classes, such as beta-blockers should be explored.  
On a final note, this future work could well be complemented by the examination of “beat-to-beat” 
changes in central and peripheral nocturnal blood pressure. Kario et al engineered a novel device 
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specifically for OSA patients that is triggered to measure BP surges that occur immediately following 
hypoxic episodes.11  Routine ambulatory BP monitoring records BP at set 15-minutely or 30-minutely 
intervals, running the risk of missing the true BP spikes that occur following apnoeic events. These 
exaggerated sleep BP surges may be responsible for triggering cardiovascular events in the OSA 
population. In a small cross-over study of patients with OSA, they found that the nocturnal 
administration of the beta blocker carvedilol was superior to the calcium channel blocker nifedipine 
in reducing the large BP surges that followed hypoxic events, which would have been undetected by 
routine BP monitoring.11 This oxygen-triggered device represents another strategy specifically 
designed to cater to the unique pathophysiology underlying hypertension in OSA. This technique has 
a significant role to play in future chronotherapy studies in OSA, and could be enhanced to measure 
central BP concurrently. This way, the true effect of the acute and massive BP surges that occur at the 
termination of apnoeic events on left ventricular afterload can be better appreciated. These studies 
are currently underway in our laboratory.  
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